



Planet Depos®
We Make It *Happen*™

Transcript of Heather J. Roberts, M.D., FAAD

Date: July 25, 2025

Case: Biofrontera, Inc., et al. -v- Sun Pharmaceutical Industries, Inc. (PTAB)

Planet Depos

Phone: 888.433.3767 | **Email:** transcripts@planetdepos.com

www.planetdepos.com

Michigan #8598 | Nevada #089F | New Mexico #566

WORLDWIDE COURT REPORTING & LITIGATION TECHNOLOGY

BIOFRONTERA EXHIBIT 1028

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

BIOFRONTERA INC., BIOFRONTERA BIOSCIENCE GMBH,
BIOFRONTERA PHARMA GMBH, and BIOFRONTERA AG
Petitioner,
v.
SUN PHARMACEUTICAL INDUSTRIES, INC.
Patent Owner.

Case IPR2024-01312
Patent 11,697,028

ORAL AND VIDEOCONFERENCED DEPOSITION OF
HEATHER J. ROBERTS, M.D., FAAD
JULY 25, 2025
(Reported remotely.)

1
2
3 ORAL AND VIDEOCONFERENCED DEPOSITION OF
4 HEATHER J. ROBERTS, M.D., FAAD, produced as a
5 witness at the instance of the Petitioner, taken
6 in the above-styled and -numbered cause on the
7 25th day of July, 2025, A.D., beginning at 9:07
8 a.m. CDT to 12:55 p.m., before Kelly Hassell, RPR,
9 CLR, CSR, in and for the State of Texas, located
10 in San Francisco, California, in accordance with
11 the PTAB Rules of Civil Procedure and the
12 agreement hereinafter set forth.
13
14
15
16
17
18
19
20
21
22

R E M O T E A P P E A R A N C E S

FOR THE PETITIONER:

MR. BRIAN J. LARIVEE, ESQ.
One International Place
Suite 3900
Boston, MA 02110
(617) 406-0335
blarivee@polsinelli.com
-and-

MR. JAMES MURPHY, ESQ.
Polsinelli PC
1000 Louisiana Street
Suite 6400
Houston, TX 77002
(713) 374-1600
jpmurphy@polsinelli.com

FOR THE PATENT OWNER:

MS. GABRIELLE HIGGINS, ESQ.
Desmarais LLP
101 California Street
Suite 3000
San Francisco, CA 94111
(415) 573-1902
ghiggins@desmaraisllp.com
-and-

MR. RAYMOND HABBAZ, ESQ.
Desmarais LLP
230 Park Avenue
26th Floor
New York, NY 10169
(212) 351-3400
rhabbaz@desmaraisllp.com

ALSO PRESENT:

DR. BRIDGET BELCHER - Desmarais LLP
MS. MADDIE REIF - Remote technician

I N D E X

Appearances.....	Page	3
Stipulations.....	Page	11
Exhibit List.....	Page	5
Direct Examination by Mr. Larivee.....	Page	8
Cross-Examination by Ms. Higgins.....	Page	118
Redirect Examination by Mr. Larivee.....	Page	121
Signature and Corrections.....	Page	124
Reporter's Certificate.....	Page	125

(REPORTER'S NOTE: Quotation marks are used for clarity and do not necessarily reflect a direct quote.)

EXHIBITS

(Retained by Counsel)

EXHIBIT NO.	DESCRIPTION	PAGE
Exhibit 1014	United States Patent Number 6,223,071	65
Exhibit 1022	Highlights of Prescribing Information	112
Exhibit 2015	Declaration of Heather J. Roberts, M.D., FAAD	18
Exhibit 2016	Curriculum vitae of Dr. Roberts	27
Exhibit 2018	How to use LEVULAN KERASTICK + BLU-U	85
Exhibit 2023	Photodynamic Therapy web page	31
Exhibit 2024	How Much Space Does a BLU-U Require?	98
Exhibit 2049	Supplemental Declaration of Heather J. Roberts, M.D., FAAD	103

1 P R O C E E D I N G S

2 THE REMOTE TECHNICIAN: Thank you
3 to everyone for attending this proceeding
4 remotely, which we anticipate will run smoothly.
5 Please remember to speak slowly and do your best
6 not to talk over one another. Please be aware we
7 are recording this proceeding for backup purposes.
8 Any off-the-record discussions should be had away
9 from the computer. Please remember to mute your
10 mic for those conversations.

11 Please have your video enabled to
12 help the reporter identify who is speaking. If
13 you are unable to connect with video and are
14 connecting via phone, please identify yourself
15 each time before speaking.

16 We will provide a complimentary
17 unedited recording of this deposition with the
18 purchase of a transcript. I apologize in advance
19 for any technical-related interruptions. Thank
20 you.

21 THE COURT REPORTER: The time on
22 the record is 9:07 a.m. Central Time.

1 If counsel could please state their
2 appearances for the record.

3 MR. LARIVEE: I'm Brian Larivee for
4 the Biofrontera Petitioners. With me is James
5 Murphy.

6 MS. HIGGINS: This is Gabrielle
7 Higgins from the Desmarais firm. With me is
8 Dr. Bridget Belcher and Mr. Raymond Habbaz,
9 representing the Patent Owner, Sun Pharma.

10 MR. LARIVEE: Good morning,
11 again --

12 THE COURT REPORTER: I'm sorry.

13 MR. LARIVEE: -- Doctor --

14 THE COURT REPORTER: I'm sorry.

15 I'm Kelly Hassell, Certified
16 Shorthand Reporter, located in Dallas, Texas.
17 The witness is located in San Francisco,
18 California. My Texas CSR number is 5729.

19 If you could raise your right hand,
20 please.

21 (The witness was duly sworn.)

22 THE COURT REPORTER: Thank you.

1 You may proceed.

2 HEATHER J. ROBERTS, M.D., FAAD,
3 having been first duly cautioned and sworn to
4 testify the truth, the whole truth and nothing but
5 the truth, testified on her oath as follows:

6 DIRECT EXAMINATION

7 BY MR. LARIVEE:

8 Q Good morning, again, Dr. Roberts. I'm
9 Brian Larivee from Polsinelli. Again, I'm
10 representing Biofrontera.

11 Are you being represented by
12 counsel today?

13 A Yes.

14 Q And who is representing you?

15 A Desmarais.

16 MS. HIGGINS: To -- to be clear, we
17 are representing the Patent Owner, Sun Pharma.

18 MR. LARIVEE: Okay.

19 Q (BY MR. LARIVEE) And, Dr. Roberts, you
20 understand that you're being deposed today in
21 the -- in the inter partes review numbered
22 IPR 202401312 pertaining to U.S. Patent

1 Number 11,697,028 that is presently before the
2 United States Patent and Trademark Office,
3 correct?

4 A Yes, that is correct.

5 Q And before we get started today, I've
6 got some instructions for you, to try to help the
7 deposition go more smoothly.

8 First, I'm going to be asking you
9 some questions, and you're going to be answering
10 the questions under oath.

11 Do you understand?

12 A Yes, I understand.

13 Q And so you understand you've been
14 sworn -- you've been -- you have been sworn to
15 tell the truth, and the effect is the same as if
16 you were testifying in court, right?

17 A Yes.

18 Q And, now, the court reporter will be
19 taking everything down that is being said here
20 today, so it's important that we don't talk over
21 each other. Instead, you should wait until I
22 finish my question before you start your answer,

1 and I will wait until you finish your answer
2 before starting my next question.

3 Do you understand?

4 A Yes, I understand.

5 Q We'll be taking breaks periodically
6 throughout the day. And if you feel you need a
7 break, for the restroom or for any other reason,
8 please ask. However, if a question is pending, I
9 just would ask that you answer the question before
10 we take the break.

11 Do you understand?

12 A Yes, I understand.

13 Q Sun Pharma's attorneys may be making
14 objections today, which are for the Patent Office
15 to consider at a later date. You're required to
16 answer my questions, even if there is an
17 objection, unless your attorney instructs you not
18 to answer.

19 Is that clear?

20 A Yes, that's clear.

21 Q Now, after the deposition is over, the
22 court reporter will repair -- will prepare a

1 transcript that contains the questions and the
2 answers and the objections. And at that point,
3 you'll have an opportunity to review the
4 transcript and prepare a statement of changes.

5 Do you understand that?

6 A Yes, I do.

7 Q Okay. Finally, this is a remote
8 deposition. You understand that we'll be
9 presenting exhibits on the screen before you,
10 right?

11 A Yes, I do.

12 Q And I will ask the reporter to put up
13 the exhibit and give you control of the exhibit so
14 that you can scroll through it and see what it is.
15 And then I -- after you've had a chance to look, I
16 will direct you to certain areas of the document,
17 and you'll have an opportunity to answer questions
18 about the document. Okay?

19 A Yes. That sounds fine.

20 Q And do you have any paper documents in
21 the room with you this morning?

22 A I have the copies of my declarations.

1 Q Okay. Could you please state your full
2 name for the record?

3 A My full name is Heather Joy Roberts.

4 Q And, Dr. Roberts, have you used any
5 other names professionally?

6 A No, I have not.

7 Q And, Dr. Roberts, is there any reason,
8 such as a physical or mental condition, unusual
9 stress, being under the influence of a substance,
10 that would prevent you from answering my questions
11 fully and truthfully today?

12 A No, there is not.

13 Q Okay. Dr. Roberts, have you ever had
14 your deposition taken before?

15 A Once before.

16 Q And when -- when was that time you had
17 your deposition taken?

18 A That was around 1999.

19 Q And what was the case about?

20 MS. HIGGINS: And I caution the
21 witness not to reveal any confidential information
22 about that case. You can identify the case.

1 A That case was a chemical exposure, and I
2 was called in to give my opinion as to whether the
3 chemical exposure caused a subsequent rash years
4 later.

5 Q (BY MR. LARIVÉE) Okay. Do you recall
6 who the parties were in that case?

7 A Yes.

8 Q And who were those parties?

9 A I'm not at liberty to say.

10 Q Okay. And were you serving as an -- as
11 an expert witness in that case?

12 A Yes.

13 Q Have you served as an expert witness in
14 any other cases?

15 A Yes, I have.

16 Q And what types of cases have you served
17 as an expert witness in?

18 A Mainly medical malpractice cases.

19 Q And have you ever served as an expert
20 witness in a patent case before?

21 A No, I have not.

22 Q Okay. Now, with -- you -- you mentioned

1 you only had one deposition. Have you ever
2 testified in court?

3 A No, I have not.

4 Q What did you do to prepare for today's
5 deposition?

6 MS. HIGGINS: And I caution the
7 witness not to reveal any communications with
8 counsel.

9 A I met with counsel and reviewed
10 documents listed in my declaration.

11 Q (BY MR. LARIVEE) Okay. Were there --
12 about how long did you meet with counsel for?

13 A Less than 15 hours.

14 Q And who was present during those
15 meetings?

16 A Myself, Gabrielle Higgins, and Bridget
17 Belcher.

18 Q Was anyone else present by phone or
19 videoconference?

20 A No.

21 Q Did any of the documents you reviewed
22 during your preparation refresh your recollection

1 about the opinions you offered in this case?

2 A It refreshed some items of technology in
3 general.

4 Q And -- and what were those items of
5 technology in general?

6 A Just some of the studies that have been
7 done in the past.

8 Q What kind of studies?

9 A Studies by Dr. Gold pertaining to using
10 BLU-U for acne.

11 Q Okay. Just generally, Dr. Roberts, what
12 documents pertaining to this case have you
13 reviewed?

14 MS. HIGGINS: And I'm going to
15 caution the witness to -- you can answer the
16 question generally. You're not to reveal
17 communications with counsel.

18 A So the documents that I've reviewed is
19 information regarding the BLU-U, the paper by
20 Dr. Gold titled "Therapeutic and Aesthetic Uses of
21 Photodynamic Therapy, Part Two of a Five-Part
22 Series" on lasers and light treatments for acne

1 vulgaris.

2 I reviewed Dr. Michael Ehrenreich's
3 declaration.

4 And then I did a -- I had a cursory
5 look at the '028 patent.

6 And then any other exhibits that we
7 cite -- that I cite in my declaration as noted.

8 Q (BY MR. LARIVÉE) Okay. Do you know
9 Dr. Michael Ehrenreich professionally?

10 A No, I do not.

11 Q You mentioned that you -- you met with
12 counsel for less than 15 hours in preparation for
13 this deposition. On how many occasions did you
14 meet with counsel?

15 A We started meeting last --

16 MS. HIGGINS: Before this
17 deposition, correct?

18 MR. LARIVÉE: Yes, before this
19 deposition.

20 MS. HIGGINS: You can answer the
21 question.

22 THE WITNESS: Okay.

1 A We started meeting around last December,
2 periodically, by Zoom.

3 Q (BY MR. LARIVEE) So when you mentioned
4 less than 15 hours, that's inclusive of -- is that
5 inclusive of all the work you've done in this
6 case?

7 A That's inclusive of all the work I've
8 done up until arriving here for the deposition.

9 Q Okay. So to be clear, in total,
10 you've -- you've billed about 15 hours to this
11 case up until this morning?

12 A Less than 15.

13 Q Thank you.

14 Have you spoken to anyone, other
15 than your attorneys, about this case?

16 A No, I have not.

17 Q Have you -- have you posted to social
18 media at all about this case?

19 A No, I have not.

20 Q Dr. Roberts, do you recall when
21 Desmarais LLP approached you about serving as an
22 expert witness in this case?

1 A I believe it was around November of
2 2024.

3 Q And were you formally retained in
4 November 2024 as well?

5 A I don't recall if it was -- I don't
6 know.

7 Q Before November 2024, had you had any
8 contact with -- with the Desmarais law firm or
9 Attorney Higgins?

10 A We may have spoken in October, but it
11 was not before October, that I can recall.

12 MR. LARIVÉE: Could we please
13 have -- Ms. Reif, could we please have
14 Exhibit 2015 published for the witness?

15 THE REMOTE TECHNICIAN: Absolutely.
16 Stand by.

17 (Exhibit 2015 marked.)

18 Q (BY MR. LARIVÉE) Dr. Roberts, the --
19 the exhibit tech has -- has put Exhibit 2015 up on
20 the screen. Do you have the ability to scroll
21 through that exhibit?

22 THE REMOTE TECHNICIAN: So all you

1 have to do, ma'am, is click on the screen, and
2 then you can use the mouse to move through.

3 A Yes, I do have that ability.

4 Q (BY MR. LARIVEE) All right.

5 Dr. Roberts, I'll -- I'll represent Exhibit 2015
6 is your declaration, but you don't have to take my
7 word for it. You can scroll through the document.
8 And when you're done, I'll have a couple of
9 questions for you about it.

10 MS. HIGGINS: And, Mr. Larivee, the
11 witness has indicated she has a hard copy of
12 Exhibit 2015 in front of her. It's okay if she
13 looks at the hard copy as well, correct?

14 MR. LARIVEE: Yes, it is. That
15 is -- that's -- that's fine with me, Counsel.

16 A Yes, this is my declaration.

17 Q (BY MR. LARIVEE) Okay. Dr. Roberts, so
18 this is a true and correct copy of Exhibit 2015,
19 which is your first declaration in this case,
20 right?

21 A It appears to be so, yes.

22 Q Okay. Before I ask you any questions

1 about this document, sitting here today -- I know
2 it's been a few months since this -- this --
3 you -- you provided this declaration.

4 Are you aware of any errors in the
5 declaration or any corrections you'd like to make
6 to it?

7 A Just one minor update. There is a place
8 in the declaration where I talk about treating the
9 face and hands and arms, chest and back.

10 Q Yes.

11 A And I neglected to also include the
12 scalp, but then in the subsequent paragraph right
13 below it, I do mention the head, which, for me,
14 the head is synonymous with the scalp.

15 Q Okay. Understood.

16 And -- and could you let me --
17 could you direct me to a paragraph there?

18 A Yes. Let's see.

19 Sorry. Hang on one sec.

20 Q Take your time.

21 A Okay. So on Page 13, Paragraph 37.

22 Q Uh-huh?

1 A First sentence, "I have obtained
2 clinically effective results using BLU-U on
3 patients' faces, necks, hands, arms, chests, and
4 backs."

5 Q And so your correction is you would like
6 to add "scalp" to that list?

7 A Correct.

8 Q Okay. Understood.

9 Dr. Roberts, did you yourself write
10 this declaration?

11 A Yes, I did.

12 Q Okay.

13 MR. LARIVÉE: Ms. Reif --

14 A Can I just add a --

15 Q (BY MR. LARIVÉE) Yes, ma'am.

16 A May I add one other thing?

17 I -- in number -- Page 15,
18 Number 43 is just referencing that -- that same
19 area again. Where it just says face, neck -- or
20 "faces, necks, hands, arms, chests, and backs,"
21 and I'd like to add "scalp."

22 Q Okay. Understood.

1 MR. LARIVEE: Ms. Reif, could I
2 please have control of the document.

3 THE REMOTE TECHNICIAN: You have
4 control.

5 MR. LARIVEE: All right. Thank
6 you.

7 Q (BY MR. LARIVEE) Dr. Roberts, I want to
8 direct your attention to Paragraph 4 of the
9 document, where you state that you're compensated
10 at an hourly rate of \$900 per hour for your expert
11 services in this case.

12 Do you see that?

13 A Yes, I do.

14 Q Is that -- is that statement correct?

15 A That statement is correct.

16 Q And that is your standard rate?

17 A That is my standard rate.

18 Q And have you used that standard rate for
19 any other consulting work?

20 A Yes, I have.

21 Q And could you briefly describe that --
22 that consulting work?

1 MS. HIGGINS: And, once again, do
2 not reveal confidential information. If you --

3 THE WITNESS: Uh-huh.

4 MS. HIGGINS: -- if you can, other
5 than that, generally describe it, please an- --
6 you can answer the question.

7 THE WITNESS: Okay.

8 A That is my standard rate for consulting
9 whenever I'm going to be away from my practice.

10 Q (BY MR. LARIVÉE) Okay. Also in
11 Paragraph 4, you state that your compensation "is
12 not dependent on the outcome of, or any issue in
13 relation to, the present IPR." Is that right?

14 A That is correct.

15 Q Is any part of your compensation
16 dependent on the substance of your opinions?

17 A No, it is not.

18 Q Is the total amount of compensation that
19 you can receive for your work in this case capped
20 or limited in any way?

21 A No, it is not.

22 Q Other than your role as an expert

1 witness in this IPR, do you have any involvement
2 with Sun Pharma concerning the '028 patent or the
3 subject matter of this litigation?

4 A No, I do not.

5 Q And other than your role as an expert
6 witness, do you have any involvement with
7 Biofrontera concerning the subject matter in this
8 litigation?

9 A No, I do not.

10 Q Do you have any financial interest in
11 the '028 patent or any other financial interest
12 relating to the present litigation or Sun
13 Pharmaceuticals?

14 MS. HIGGINS: And, Mr. Larivee, in
15 your question, when you say "the present
16 litigation," you're referring to this IPR?

17 MR. LARIVEE: Yes.

18 A No, I do not.

19 Q (BY MR. LARIVEE) Do you own any stock
20 in Sun Pharma or Biofrontera?

21 A Not that I'm aware of.

22 Q Has Sun Pharma made any report -- any

1 payments to you in 2025 that would be reported on
2 a -- open payments this year?

3 A No, they have not.

4 Q Dr. Roberts, how did you first become
5 aware of this dispute between Biofrontera and Sun
6 Pharmaceuticals?

7 MS. HIGGINS: You can answer the
8 question. I instruct you not to reveal any
9 communications with counsel.

10 A When I was contacted by Desmarais.

11 Q (BY MR. LARIVÉE) Okay. And now,
12 Dr. Roberts, did you have any knowledge of the
13 RhodoLED XL before you were approached about
14 serving as an expert in this case?

15 A No, I did not.

16 Q And did you have any knowledge about
17 AMELUZ before you were approached about serving as
18 an expert in this case?

19 A Yes.

20 Q And what did you know about AMELUZ
21 before being -- serving as an expert in this case?

22 A That it's a form of aminolevulinic acid.

1 Q And do you recall when you first became
2 aware of AMELUZ?

3 A No.

4 Q Do you recall how you first became aware
5 of AMELUZ?

6 A Hearing about it at educational
7 conferences.

8 Q Have you ever used AMELUZ before in your
9 practice?

10 A No, I have not.

11 Q Have you ever -- before this case, have
12 you ever studied the label of AMELUZ?

13 A No, I have not.

14 Q Now, Biofrontera makes another
15 photodynamic illuminator called the Rhodo- -- the
16 BF-RhodoLED. Have you ever heard of the
17 BF-RhodoLED before your involvement in this case?

18 A No, I have not.

19 Q Okay.

20 MR. LARIVEE: Ms. Reif, could we
21 please take down this exhibit and put up
22 Exhibit 2016.

1 THE REMOTE TECHNICIAN: Yep. Stand
2 by.

3 (Exhibit 2016 marked.)

4 Q (BY MR. LARIVÉE) Dr. Roberts, you're
5 seeing on the screen right now Exhibit 2016. What
6 is this document?

7 A A copy of my curriculum vitae.

8 Q And when was this document last updated?

9 A Probably within the last two years.

10 Q To your knowledge, is there any
11 significant education, employment, publications
12 that are not listed in this document?

13 A I don't have my legal expertise work
14 listed in here, but --

15 THE WITNESS: Can you scroll down?

16 THE REMOTE TECHNICIAN: You have
17 control, Doctor.

18 THE WITNESS: It's not -- oh,
19 there it is.

20 A That's the only thing that I see is not
21 listed.

22 Q (BY MR. LARIVÉE) Okay. Dr. Roberts,

1 directing your attention to board certifications
2 on the first page.

3 MS. HIGGINS: Mr. Larivee, may I
4 put a hard copy of Exhibit 2016 in front of the
5 witness, if it's easier for her?

6 MR. LARIVEE: Absolutely. If she
7 would prefer that, that would be fine.

8 THE WITNESS: Thank you.

9 MR. LARIVEE: If she's got a hard
10 copy, could I please have control on the soft
11 copy?

12 MS. HIGGINS: The witness has a
13 hard copy in front of her.

14 MR. LARIVEE: Wonderful.

15 Q (BY MR. LARIVEE) Dr. Roberts, do you
16 have any other board certifications than those
17 listed here?

18 A No, I do not.

19 Q Do you have any certification in, for
20 instance, Mohs micrographic surgery?

21 A No, I do not.

22 Q The next section down is "Academic

1 Appointments."

2 What was your role as a clinical
3 associate professor of dermatology at USC/Keck
4 School of Medicine?

5 A I was one of the voluntary surgical
6 attendings in a weekly clinic. I was teaching
7 medical students and dermatology residents
8 dermatologic surgical procedures, as well as laser
9 procedures and laser technology.

10 Q Okay. What types of dermatological
11 surgeries were you -- were you teaching?

12 A Non-Mohs excisions of cutaneous
13 malignancies; removal of benign growths and lumps;
14 drainage of and packing of abscesses; hair
15 transplantation; liposuction; sclerotherapy,
16 injection of leg veins; chemical peels; tattoo
17 removal treatments with laser and microder- -- and
18 regular dermabrasion; pulsed dye laser treatments;
19 CO2 laser resurfacing procedures.

20 I think that covers most of what I
21 taught them.

22 Q Okay. Anything else?

1 A Not that's coming to mind at this
2 moment.

3 Q And, Dr. Roberts, under the section for
4 "Work Experience," I see Cedars-Sinai, I see USC,
5 but where -- where do you presently work?

6 A I have my own private practice in Los
7 Angeles.

8 Q And what is that practice called?

9 A Heather J. Roberts, MD, a Medical
10 Corporation.

11 Q And, Dr. Roberts, how long have you --
12 have you been operating Heather J. Roberts, MD, a
13 Medical Corporation?

14 A 24 years.

15 Q Okay. So you -- you founded the
16 practice in 2001?

17 A Correct.

18 Q And has that been your -- your primary
19 employment since 2001?

20 A Yes, it has.

21 Q And has that employment been continuous?
22 Have there been any gaps or -- or breaks from that

1 practice?

2 A No, there have not.

3 MR. LARIVEE: Okay. Could we
4 please have Exhibit 2023?

5 THE REMOTE TECHNICIAN: Stand by.

6 (Exhibit 2023 marked.)

7 Q (BY MR. LARIVEE) Dr. Roberts, you're
8 being shown Exhibit 2023, entitled "Photo-" --
9 it's Sun Pharmaceuticals Exhibit 2023. It is a
10 printout -- or -- or strike that.

11 What is this document?

12 A This is a copy of the page from my
13 website on photodynamic therapy.

14 Q Okay. Please feel free to take a moment
15 to look at the exhibit, and then I'm going to have
16 a couple of questions for you.

17 A Okay.

18 Q Okay. I want to direct your
19 attention --

20 MR. LARIVEE: If -- if I could have
21 control of the document, please.

22 THE REMOTE TECHNICIAN: You have

1 it.

2 MR. LARIVÉE: Thank you.

3 Q (BY MR. LARIVÉE) Dr. Roberts, just
4 directing your attention to this first paragraph
5 here. It begins, "With age comes wisdom, but also
6 telltale years -- telltale signs of years spent in
7 the sun, smoking, and hormonal changes."

8 Do you see that paragraph?

9 A Yes, I do.

10 Q And it goes on to talk about fine lines,
11 deeper wrinkles, precancerous spots, brown spots,
12 and broken capillaries, right?

13 A Yes.

14 Q And it -- it says that "PDT offers
15 another option to address all these changes with
16 one modality."

17 Do you see that?

18 A Yes, I do.

19 Q And then it says, "The overall cosmetic
20 improvements in the skin will delight you."

21 Do you see that?

22 A Yes, I do.

1 Q And so would you agree with me here that
2 the -- that the focus of this paragraph is on
3 cosmetic improvements to a patient's skin?

4 A No, I would not.

5 Q And -- and why would you disagree with
6 me here?

7 A Because it's not giving a more focused
8 weighting. It's just listing a variety of things
9 that patients can see improvements with when
10 they're doing photodynamic therapy.

11 Q Okay. It's not giving a weighting; is
12 that -- is that your testimony?

13 A Yes, it is.

14 Q Okay. And so looking back at that
15 second sentence there, we have a number of things
16 listed, right?

17 A Yes.

18 Q Fine lines, deeper wrinkles,
19 precancerous spots, brown spots, and broken
20 capillaries. That's, by my count, five different
21 items.

22 A Correct.

1 Q And fine lines, that's cosmetic, right?

2 A That is cosmetic.

3 Q Deeper wrinkles, that's cosmetic, right?

4 A That is cosmetic.

5 Q Broken capillaries, is that cosmetic?

6 A Sometimes cosmetic; other times,
7 medical.

8 Q Are brown spots cosmetic or medical?

9 A They can be both.

10 Q And precancerous spots, those are
11 medical, right?

12 A Correct.

13 Q And the last sentence in this section
14 says, "Your face will grow [sic] and be more
15 radiant as your new healthy skin emerges."

16 Do you see that?

17 A I do.

18 Q And that's cosmetic, right?

19 A Not necessarily.

20 Q And why not?

21 A Because when patients have a lot of sun
22 damage -- and practicing in Southern California

1 for almost, now, 30 years, I see severe sun damage
2 every single day. And with that sun damage comes
3 more sallow appearance to the skin. The way light
4 is reflected off the skin when you have numerous
5 actinic keratoses is diminished.

6 And so by treating a medical
7 problem, which is the actinic keratoses, then
8 you're going to see that your overall light
9 reflection, appearance of your skin is going to be
10 brighter. It's going to have a little glow.

11 And even when I do my
12 consultations, the first thing I always say is,
13 this is not a cosmetic treatment. This is to
14 treat the precancerous spots that you have on your
15 face, and the side benefit that you may see is
16 improvement in fine lines and wrinkles,
17 improvement in capillaries, smoothing of skin
18 surface texture.

19 So it is not, you know, presented
20 as a cosmetic treatment compared to all the other
21 cosmetic treatments that I do in my office.

22 Q Okay. I want to direct your attention

1 to this paragraph at the top of Page 2. It
2 begins, "PDT is a special treatment."

3 And can you just read that
4 paragraph to yourself and nod when you're ready
5 for a question on it.

6 A Okay.

7 Q And you state that "PDT can be performed
8 with your Lumecca Intense Pulsed Light, IPL,
9 device or Vbeam laser to intensify the results
10 compared to standard laser treatments."

11 Do you see that?

12 A Yes, I do.

13 Q And how -- how is PDT performed with
14 the -- with those devices?

15 A So photodynamic therapy refers to a
16 treatment where you're using a topical
17 photosensitizer with a light source. So it
18 doesn't specify what type of light source. In
19 fact, in Europe, they put a topical on the
20 patients' skin and they tell them to go walk
21 around in the sun and get their -- you know, their
22 light source from the sun.

1 So there are, you know, a small
2 number of patients who want to get both a
3 combination treatment for, again, a face full of
4 actinic keratoses and they've had numerous
5 melanoma and non-melanoma skin cancers, but they
6 also want to get some cosmetic benefit in the
7 non-precancerous spots. Or maybe they've done,
8 you know, IP- -- or they've done IPL in the past
9 and they want to, you know, ratchet up the
10 effects.

11 So the way we do it is --
12 basically, the preparation is to, you know,
13 cleanse the face, degrease the face, do an alcohol
14 acetone scrub to get all of the surface skin cells
15 off. Then we apply the LEVULAN to the entire
16 face, and we will often, you know, let the
17 patient -- well, strike that.

18 We will then have the patient, you
19 know, wait in low-lit light for 90 minutes. And
20 then, after the 90 minutes, we remove the LEVULAN.
21 We do the laser treatment, depending on which
22 laser we're using. And then, after that, we do

1 what we call -- I've made the term -- I've created
2 the term myself, called a BLU-U boost.

3 So after they've done the full
4 laser treatment with me, then depending on how red
5 the skin looks, I will then put them under the
6 blue light and give them anywhere from one to
7 three minutes of additional blue light.

8 And then we, you know, give them
9 their aftercare regimen and put a calming thermal
10 spring water mask on the skin, an aftercare cream,
11 sunscreen, and then we give them the big, giant
12 floppy hat.

13 Q And I'm not familiar with an IPL laser.
14 What -- what is the emitting spectrum for an IPL
15 laser?

16 A So, technically, Intense Pulsed Light is
17 broadband light, so not the true definition of a
18 laser. Because, by definition, laser is one
19 wavelength of light that's amplified. So you're
20 getting a full spectrum, anywhere from 480 on some
21 devices, you can get that well all the way up to
22 800, some devices even 1,100.

1 Q Would a person of skill in the art be
2 conducting PDT with an IPL laser in the 2015 time
3 frame?

4 MS. HIGGINS: Objection; form,
5 lacks foundation.

6 You can answer.

7 A I suppose. I'm not really sure what
8 you're -- what you're getting at on that question.

9 Q (BY MR. LARIVÉE) What part of the
10 question is -- is unclear?

11 A When you're saying would a person with,
12 you know, skill in the art be performing that
13 procedure.

14 Q Okay. We can -- we can -- we'll talk
15 about person of skill in the art later, and maybe
16 we can come back to this question.

17 What is the -- what's the power
18 output of an IPL laser that you use in your
19 practice?

20 A I mean, I'd have to go back and refer to
21 the specifications.

22 Q Uh-huh.

1 A I can just tell you that when it comes
2 to the joules setting on the device, for IPL, it
3 can, you know, be as low as zero, and it can -- I
4 think it goes up to -- let me just think. I think
5 it goes up to 20. I mean, most patients are going
6 to be treated somewhere between a fluence of 8 to
7 13.

8 Q Okay. So for the IPL, you can adjust
9 the -- the fluence of the -- of the laser?

10 A Yes.

11 Q Is there any other -- are there any
12 other parameters of the IPL laser that you can
13 adjust?

14 A Yes.

15 Q And what are those parameters?

16 A You can adjust the pulse duration.

17 Q What else? Anything else?

18 A You can adjust the cutoff filter of the
19 wavelength.

20 Q Does the cutoff filter of the wavelength
21 select a particular wavelength that is output by
22 the IPL?

1 MS. HIGGINS: Objection; form.

2 A What the wavelength cutoff filter helps
3 with is, if you have a darker-skinned patient and
4 you want to be careful not to impact their natural
5 pigment, and you're trying to target their brown
6 spots or their hormonally-induced pigment, you can
7 use a cutoff wavelength that's longer. So that's
8 safer in a darker-skinned patient.

9 Q (BY MR. LARIVÉE) Okay. Are there any
10 other parameters that are adjusted with the IPL
11 laser?

12 A No. That should be it.

13 Q With respect to the Vbeam laser, what --
14 what wavelengths are used in treatment?

15 A So the Vbeam is a Pulsed Dye Laser with
16 a 595 wavelength. And, again, because it's a true
17 laser, it has one wavelength.

18 Q And does 595 nanometers correspond with
19 a particular visible color?

20 A It corresponds with targeting anything
21 that's red in the skin.

22 Q And what -- what settings on the Vbeam

1 laser can be adjusted?

2 MS. HIGGINS: Objection; lacks
3 foundation.

4 A Just like most laser devices, you can
5 adjust multiple parameters: Spot size, the
6 fluence, the pulse duration, whether you're using
7 surface cooling with a cryotherapy spurt, or no
8 cooling. That's it.

9 THE COURT REPORTER: I'm sorry.
10 Did you say "cooling"?

11 THE WITNESS: Cooling, yes.

12 Q (BY MR. LARIVÉE) And what does -- what
13 does the spot size correspond to?

14 MS. HIGGINS: Objection; form.

15 A The spot size corresponds to the depth
16 of penetration that you want to achieve and the
17 size of the target.

18 Q Okay. Let's cover those in reverse
19 order. What's the smallest size of the target you
20 can -- you can treat with the -- with the Vbeam
21 laser in your office?

22 A The spot size on the laser or the spot

1 on the skin?

2 Q Let's say on the skin.

3 A Less than a 10th of a millimeter, you
4 can.

5 Q And what's the largest spot size you
6 can -- you can treat with -- the spot size on the
7 skin?

8 A There's no limit.

9 Q So you could -- you could have a spot
10 that's 10 millimeters wide?

11 A Correct.

12 Q 20 millimeters wide?

13 A Correct.

14 Q 100 millimeters wide?

15 A Correct.

16 Q And as a dermatologist, what's the
17 benefit in being able to adjust, let's say, the
18 spot size of -- of your laser?

19 A It allows you to customize your
20 treatments to what the patient needs.

21 Q Is it generally helpful to you, as a
22 dermatologist, to be able to adjust these settings

1 to treat your patients?

2 And by "these settings," let me say
3 I include the ones you just listed, spot size,
4 fluence, pulse duration.

5 MS. HIGGINS: Objection; form,
6 overbroad.

7 A You know, there are thousands and
8 thousands of different laser, you know,
9 manufacturers and laser devices on the market, and
10 so some devices have the ability to modify
11 multiple parameters and others don't.

12 And so, again, it really depends on
13 what you're trying to treat and your level of
14 expertise with laser physics.

15 In fact, more and more companies,
16 as -- as a consultant for laser companies and when
17 they're developing technologies, they are always
18 trying to dummy down the technology and take away
19 the flexibility of being able to make changes.
20 Because in our current environment of spa
21 medicine, those nurse practitioners and
22 aestheticians in some states, they're not trained

1 the way we are to understand laser physics. So
2 they don't know how to work with technologies that
3 give flexibility, and then they burn their
4 patients, and then I end up seeing those patients
5 for complications of the burns.

6 Q (BY MR. LARIVÉE) But with your training
7 as a dermatologist, would you say that compared
8 to -- if you were looking at two Vbeam lasers, and
9 one offered the list of customizations and
10 abilities to make adjustments and the other did
11 not, would you choose the one that is more
12 adjustable?

13 MS. HIGGINS: Objection; form,
14 outside the scope.

15 A Yeah, I mean, that's such a hypothetical
16 question. I -- you know, when I buy technologies,
17 I mean, I do a deep dive researching the
18 technologies. So I can't comment on that.

19 MS. HIGGINS: Mr. Larivee, we've
20 been going for about an hour. Is now a good time
21 to take a quick break?

22 MR. LARIVÉE: Sure. I'm happy to

1 take a -- how long would you like, Counsel? Five
2 minutes?

3 MS. HIGGINS: Sure.

4 MR. LARIVÉE: 10 minutes?

5 MS. HIGGINS: Oh, let me ask the
6 witness.

7 You want five minutes or
8 10 minutes?

9 THE WITNESS: Five minutes is fine.

10 MS. HIGGINS: Okay.

11 MR. LARIVÉE: Okay. Great. I'm
12 happy to break.

13 THE COURT REPORTER: We are off the
14 record at 10:05 a.m.

15 (Break taken from 10:05 a.m. to
16 10:15 a.m.)

17 THE COURT REPORTER: We are back on
18 the record at 10:15 a.m.

19 Q (BY MR. LARIVÉE) Okay. Dr. Roberts,
20 during the break did you discuss the substance of
21 the deposition with your counsel?

22 A No, I didn't.

1 MS. HIGGINS: I was just going to
2 say, you can answer the question yes or no.

3 A No, I did not.

4 MR. LARIVÉE: Okay. Could we
5 please have back Exhibit 2023?

6 Q (BY MR. LARIVÉE) Okay. Dr. Roberts,
7 I've got a question about the -- about the
8 paragraph about two-thirds of the way down the
9 page that begins, "PDT skin rejuvenation does not
10 stop the aging process."

11 Could you please read that
12 paragraph and nod when you're ready for a
13 question?

14 A Okay.

15 Q Is a touchup procedure the same as a
16 second PDT treatment?

17 MS. HIGGINS: Objection; form.

18 A Can you repeat your question, please?

19 Q (BY MR. LARIVÉE) Is a touchup procedure
20 the same as a second PDT treatment?

21 MS. HIGGINS: Same objection.

22 A The reason I'm hesitating is in the

1 definition of touchup.

2 Q (BY MR. LARIVÉE) Okay. Well, let me
3 ask a different question.

4 What is a touchup procedure?

5 A So the reason I have it in quotes here
6 is because, again, it's not a typical touchup. So
7 a touchup really is -- so if we were doing, say, a
8 full-face laser treatment with a Vbeam for blood
9 vessels and 90 percent of the vessels were gone,
10 and there was just one blood vessel left on the
11 patient's nose that was driving them crazy and
12 they wanted to come in to just zap that one blood
13 vessel, I would call that a touchup.

14 Q Okay. What are we referencing here in
15 this paragraph? What type of procedure are you
16 referencing here --

17 A So --

18 Q -- when you say "touchup procedure"?

19 A So again, with it being in quotes, I'm
20 -- I'm doing it that way because that's language
21 that laymen will often use to -- you know, because
22 everybody with come in and say, "Can I do it once

1 and be done forever," right? And so, I mean, I
2 tongue-in-cheek will tell them, "There's only one
3 thing we're going to ever do in life, and that's
4 die."

5 So, you know, the reality is they
6 will need additional PDT treatments in the future.

7 Q And in the pre- -- preceding sentence it
8 says, "Smoking, past sun exposure, and wrinkle
9 depth will determine the number of treatments
10 needed."

11 Do you see that?

12 A Yes.

13 Q And are there any other factors that
14 might affect the number of treatments needed?

15 A Yes. So again, that one particular
16 sentence is, you know, kind of addressing more of
17 the improvement in wrinkles. So, you know, there
18 are many, many reasons for wrinkling of the skin.

19 So does that answer your question?

20 Q Well, one other question I guess I have
21 is, would the depth of the actinic keratosis
22 affect the number of PDT treatments required?

1 MS. HIGGINS: Objection; form.

2 A So with every treatment that we use for
3 treating actinic keratoses on the market,
4 including medical treatments, there's always a
5 chance of a single microscopic cell being left and
6 the actinic keratoses coming back. That's why we
7 think of it as an ongoing treatment. It's never a
8 one-and-done, and even with the medications.

9 So it's not so much to me the depth
10 as much as sometimes, like, if it's a very crusted
11 hyperkeratotic actinic keratosis, then we just
12 want to make sure the LEVULAN is penetrating. So,
13 you know, sometimes we apply extra LEVULAN to that
14 one particular spot, or I'll do some debridement
15 first to make sure the LEVULAN is going to
16 penetrate.

17 So, you know, there are different
18 ways we can manipulate the procedure to make sure
19 we're getting enough penetration into the skin.

20 Q (BY MR. LARIVÉE) Dr. Roberts, at the
21 beginning of your -- your last answer you
22 referenced every treatment that we use for

1 treating actinic keratosis on the market. And --
2 and I guess my question for you is, what are the
3 -- the methods of treatment that you use for
4 treating actinic keratosis?

5 A So cryotherapy is probably the most
6 common. Topical chemotherapy, topical immune
7 modulators, deep chemical peels, resurfacing
8 lasers, photodynamic therapy.

9 Q Okay. And -- and what percentage of
10 your practice when you're treating AKs do you use
11 photodynamic therapy?

12 A Well, as I said, because I practice in
13 southern California, definitely not as much as
14 practitioners where there's not as much sun. So I
15 would probably say, since we do most of our
16 photodynamic therapy late fall to early spring, is
17 probably less than 2 percent of the treatments
18 that I do.

19 Q And where -- what modality do you use
20 most often for treating PD- -- for treating
21 actinic keratosis?

22 A Cryotherapy.

1 Q And do you have a sense of about what
2 percentage of AKs in your practice you treat using
3 cryotherapy?

4 A I would probably say 70 to 80 percent.

5 Q And you mentioned two other -- two types
6 of topical treatments, topical che- -- chemo and
7 tropical -- topical -- there was another topical
8 one.

9 What percentage are used -- what
10 percentage of your AKs are you treating with
11 topical chemo?

12 A So many patients are doing multiple
13 modalities. So I would say, those that are
14 willing to do it, 40 to 50 percent we'll use
15 topical chemotherapy or immunotherapy.

16 Q And what per- -- percentage,
17 approximately, are you using deep chemical peels?

18 A You know, when I first started
19 practicing, that was very popular. Now it's --
20 it's so rare that patients are willing to do that,
21 because we also now have photodynamic therapy that
22 we didn't have back then.

1 I have not done a deep chemical
2 peel for actinic keratoses in probably, you know,
3 the last 12 years.

4 Q And how about lasers? What percentage
5 of -- of AKs are you treating with lasers?

6 A So I no longer have a CO2 resurfacing
7 laser in my practice, so none. If they want that
8 treatment, I refer them out.

9 Q Okay. And why would you choose PDT
10 compared to some other treatment modality?

11 A So patient compliance is a huge problem
12 when it comes to treating actinic keratoses, for a
13 variety of reasons. And so being able to give
14 them a very effective treatment, that if they can
15 just set aside one week for me of down time, and I
16 have more control over making sure all the lesions
17 I want treated are getting treated versus giving
18 them a diagram that's circled and them trying to
19 treat them at home with the topical creams.

20 MR. LARIVÉE: Okay. I think I'm
21 done with this exhibit for now.

22 Q (BY MR. LARIVÉE) Dr. Roberts, are you

1 the inventor on any patents?

2 A No, I'm not.

3 MR. LARIVEE: And could we have
4 Exhibit 2015 back?

5 Q (BY MR. LARIVEE) And, Dr. Roberts, I
6 want to direct your attention to Paragraph 8.

7 A Yes.

8 Q Okay. Let me see. And, Dr. Roberts,
9 what field do you consider yourself to be an
10 expert in?

11 A Dermatology.

12 Q And could you briefly describe the
13 knowledge, skill, experience, training, education
14 that you have that you believe -- that you believe
15 qualifies you as an expert in dermatology?

16 A Sure. So starting with my undergraduate
17 training and degree, with my background in
18 biochemistry, allows me to have a deeper insight
19 into biochemical makeup of medications and topical
20 skin care products.

21 Doing two residencies, one in
22 internal medicine and later one in dermatology,

1 gives me a unique perspective on the systemic
2 manifestations of dermatologic diseases.

3 Then doing my dermatology training
4 at a very prestigious, very large county facility
5 at USC, we would see such a variety of patients
6 and cases and skin types that by the time we
7 graduated, I mean, we almost became too blas
8 about seeing such unique, you know, diseases that
9 in my over 20 years since graduating I've never
10 seen again. So you're -- you're dealing with just
11 an incredible, you know, teaching foundation at a
12 facility like USC.

13 And then, you know, ever since
14 then, as you can see from my declaration, and I
15 have had a wide variety of, you know, both
16 volunteer experiences, teaching experiences, and
17 seeing my own patients. And, you know, I have
18 medical students and students from UCLA that are
19 hoping to go to medical school, physician's
20 assistant school, or nursing school that come and
21 work in my office for, you know, a year or two at
22 a time. And so I'm constantly teaching them and

1 teaching my patients, because I love to do patient
2 education as part of my treatments. And I also
3 spend a significant amount of time, you know,
4 keeping up with both conferences that now are
5 eventually remote and recorded and available to go
6 back and listen to on a regular basis.

7 So I feel that, yeah, all of that
8 put together with this many years of training on
9 the job qualifies me as an expert in dermatology.

10 Q Thank you.

11 MR. LARIVÉE: Could -- I'm going
12 to -- could we see Paragraph 13? Or could I
13 please have control of the document?

14 Q (BY MR. LARIVÉE) Dr. Roberts, your
15 declaration states in Paragraph 13 that you have
16 20 years of experience with light-based
17 technologies, including photodynamic therapy.

18 Could you please explain briefly
19 how photodynamic therapy works?

20 A Sure. Photodynamic therapy basically,
21 again, is using a photosensitizer, which we
22 typically use LEVULAN, and a light source to cause

1 a chemical reaction in the skin to destroy the
2 cells that we're trying to target.

3 Q And can you explain how photodynamic
4 diagnosis works?

5 MS. HIGGINS: Objection; form.

6 A I had never really heard photodynamic
7 diagnosis as a term until this case. I assume
8 what they mean is that, once you see the reaction
9 from photodynamic therapy, you can then confirm
10 for yourself that the patient has actinic
11 keratoses.

12 Q (BY MR. LARIVÉE) In Paragraph 28, which
13 I'm showing here, it states that you have used Sun
14 Pharma's BLU-U 4170 device in your dermatology
15 practice, correct?

16 A Yes.

17 Q And if we look down at Paragraph 33 it
18 says that you first purchased a BLU-U for your
19 practice in 2004; is that right?

20 A Yes.

21 Q And so you've been using that BLU-U for
22 over 20 years, correct?

1 A That is correct.

2 Q And over those 20 years, you've
3 conducted approximately 2,400 treatments, correct?

4 A Correct.

5 Q And, Dr. Roberts, did you conduct all
6 2,400 treatments with -- with the BLU-U you
7 purchased in 2004?

8 A Yes.

9 Q And were all those treatments for
10 actinic keratosis and acne, or were there other
11 conditions you were treating?

12 A No, just those two. And the majority
13 are actinic keratoses.

14 Q Over the 21 years that you -- you've had
15 your BLU-U, how has the device been maintained?

16 A So the beauty of the BLU-U is, compared
17 to all my other devices, there's really no
18 maintenance. I mean, I'm just -- I'm very
19 meticulous, and my staff know it, about being very
20 careful when they're moving the machine. We don't
21 slam it into walls, and they don't let patients,
22 you know, just stand up and lift away the thing on

1 their own. I mean, I'm very -- I'm very careful
2 with my equipment.

3 Q During the 20-plus years that you've --
4 you've owned this device, have the fluorescent
5 light bulbs been replaced?

6 A No, they have not.

7 Q Do you recall approximately how much the
8 device cost when you bought it?

9 A I believe it was around 8,000.

10 Q And when you conduct PDT for actinic
11 keratosis, what does your -- what does your office
12 charge the patient?

13 MS. HIGGINS: Objection; form.

14 A I believe our current fee for actinic
15 keratoses is around 800 per treatment.

16 Q (BY MR. LARIVÉE) And when you conduct
17 PDT for acne, about how often -- or about how much
18 does your -- your office charge for that
19 treatment?

20 MS. HIGGINS: Same objection.

21 You can answer.

22 A Since we rarely do PDT for acne and it

1 often is, you know, a series of three treatments,
2 the treatment -- I think we're now I want to say
3 at 500, maybe 600 per treatment.

4 Q (BY MR. LARIVÉE) When you treat for
5 acne, do you apply LEVULAN, or -- or is it just
6 exposure to the light?

7 A So we have two different options, so
8 yes. If we're doing photodynamic therapy, then
9 that means we're applying LEVULAN, and that's the
10 price I just quoted. We have many more patients
11 who will just come in and just do plain blue
12 light, and those treatments are \$50 a treatment.

13 Q Okay. About -- about how many times per
14 month would you say that you use the -- the BLU-U
15 to treat patients?

16 A So it really varies. I mean, acne
17 patients, you know, teenagers typically, you know,
18 come in for just plain blue light twice a week.
19 And again, depending on their school schedule or
20 their summer schedule. So we can have some months
21 where we've got three or four teenagers coming in
22 two, sometimes three times a week.

1 And then, you know, again, from
2 kind of late spring or early summer until
3 November, maybe I have one patient doing
4 photodynamic therapy, because they're all outside.

5 And then between -- once the
6 holidays pass between, you know, either November,
7 December, January, until early spring, then, you
8 know, we may have two to ten people, you know,
9 doing photodynamic therapy.

10 It just really varies.

11 Q Okay. So there's a seasonality to
12 which --

13 A Yes.

14 Q -- people are getting PDT?

15 A Right. Right.

16 Q Dr. Roberts, I have a couple of
17 questions for you about Paragraph 31 that I'm
18 showing on the screen right now. Can you just nod
19 when you've had a chance to look at Paragraph 31?

20 A (Indicating).

21 Q Okay. So in your declaration,
22 Dr. Roberts, you're -- you're pointing to Sun

1 Pharma's website that explains that the BLU-U
2 device is used in combination with LEVULAN
3 KERASTICK for photodynamic therapy to treat
4 actinic keratosis, right?

5 A Correct.

6 Q And LEVULAN KERA- -- KERASTICK contains
7 20 percent aminolevulinic acid HCl, right?

8 A HCL, but yes.

9 Q Forgive me.

10 And -- and why is a 20 percent
11 concentration of aminolevulinic acid used?

12 MS. HIGGINS: Objection; form.

13 A I -- I can't answer that question. I
14 don't know why they chose that percentage.

15 Q (BY MR. LARIVÉE) And if we look at
16 Paragraph 32, you state in your declaration
17 that -- that -- that Sun Pharma's website states
18 that the BLU-U covers an active area of 214 square
19 inches, 14 times larger than the red light of
20 other PDT treatments.

21 Do you see that?

22 A Yes.

1 Q And what is the -- what is the red light
2 of other PDT treatments referring to?

3 A I mean, this I'm just quoting directly
4 from their website, so I can't tell you specific
5 red light treatments they're referring to.

6 Q Dr. Roberts, you -- you testified a few
7 minutes ago that you -- you've been using the same
8 BLU-U device since 2004.

9 Do you know whether the -- the
10 fluent output of that BLU-U device is the same now
11 as it was in 2004 when you first obtained it?

12 MS. HIGGINS: Objection; form.

13 A We don't specifically measure the fluent
14 output of the device, but I can tell you the
15 results are the same.

16 Q (BY MR. LARIVÉE) Have you published any
17 papers or articles regarding photodynamic therapy?

18 A No, I have not.

19 Q Dr. -- Dr. Roberts, other than -- I'm
20 directing your attention to Paragraph 6,
21 "Information Considered."

22 Do you see that section?

1 A Yes.

2 Q Other than what's noted in your
3 declaration here, were you provided with any other
4 assumptions by Desmarais that you relied upon in
5 forming the opinions that you expressed in your
6 report?

7 MS. HIGGINS: You can answer the
8 question yes or no. Do not reveal communications
9 with counsel.

10 A No.

11 Q (BY MR. LARIVÉE) Did you review any
12 materials in connection with the preparation of
13 your declaration that are not listed in your
14 reports or Materials Considered list?

15 A No.

16 Q In connection with preparing this
17 declaration, were you provided with any facts or
18 data that you did not consider in forming the
19 opinions expressed in your declaration?

20 MS. HIGGINS: Once again, you can
21 answer the question yes or no. Do not reveal any
22 communications with counsel.

1 A No.

2 MR. LARIVÉE: Could we please have
3 Exhibit 1014?

4 THE REMOTE TECHNICIAN: Stand by.
5 (Exhibit 1014 marked.)

6 THE REMOTE TECHNICIAN: Doctor, you
7 have control.

8 THE WITNESS: Okay.

9 Q (BY MR. LARIVÉE) Dr. Roberts, my first
10 question for you is, you've been shown Exhibit
11 1014 with the -- which is U.S. Patent
12 Number 6,223,071 to Lundahl. I'm going to have a
13 question for you on Figure 2 in a moment.

14 But my first question, Dr. Roberts,
15 is, have you seen in this document before?

16 A So I don't recall seeing that diagram on
17 the bottom of the copy of the patent that I was
18 given with the patient's head in the -- in a
19 device.

20 Q So you -- you don't recall seeing that
21 diagram before?

22 A I mean, it's not on the copy that I was

1 given to review. So let me just...

2 Page 3, Figure 1. Maybe it's just
3 smaller on mine.

4 MS. HIGGINS: To be clear, Counsel,
5 you're asking her if she's ever seen this document
6 before?

7 MR. LARIVEE: That's my question,
8 yes.

9 A Yeah, these are not the same-looking
10 figures on the document that I've reviewed.

11 So yeah, this is Patent '071. I
12 have not seen this patent, so I can't comment on
13 this patent that I've never seen.

14 MR. LARIVEE: Okay. Could I please
15 have control of the document?

16 THE REMOTE TECHNICIAN: You have
17 it.

18 MR. LARIVEE: Let me take this down
19 for a second. Just take this down for just one
20 second.

21 Q (BY MR. LARIVEE) Dr. Roberts, do you
22 know who DUSA Pharmaceuticals is?

1 A Yes.

2 Q And when you bought your BLU-U, did you
3 buy it from DUSA Pharmaceuticals?

4 A Yes.

5 Q And when you bought your LEVU- --
6 LEVULAN, did you -- did you buy it from DUSA
7 Pharmaceuticals?

8 A Yes.

9 MR. LARIVÉE: Could we please have
10 the -- the patent back up?

11 MS. HIGGINS: And to be clear,
12 we're referring to the '071 patent, Exhibit 1015?

13 MR. LARIVÉE: 10- -- I think it's
14 1014.

15 MS. HIGGINS: 1014, okay.

16 MR. LARIVÉE: But I -- I could -- I
17 could be wrong. 1014 is what I have in my
18 records.

19 MS. HIGGINS: Can you scroll -- can
20 you scroll down just so we can see the exhibit
21 number, please? Thank you.

22 MR. LARIVÉE: Yeah, that's 1014.

1 Q (BY MR. LARIVEE) Dr. Roberts, do you
2 see here the assignee on the left side of the
3 screen, DUSA Pharmaceuticals?

4 A Yes.

5 Q Dr. Roberts, you understand that you're
6 -- you're testifying in -- in connection with
7 what's called an inter partes review, correct?

8 A Correct.

9 Q And what is your understanding of what
10 an inter partes review is?

11 MS. HIGGINS: And I'm going to
12 instruct the witness, if your only understanding
13 comes from counsel, to not answer the question.
14 But if you have a general understanding other than
15 that, you can say so.

16 A Yeah, I'm not going to address that.

17 MR. LARIVEE: Counsel, I think your
18 objection is overbroad, but let me see if I can
19 come at it a different way.

20 Q (BY MR. LARIVEE) Dr. Roberts -- and
21 this is just a yes-or-no question -- do you
22 understand that this case concerns Biofrontera's

1 contention that the '028 patent is invalid in view
2 of the prior art?

3 MS. HIGGINS: You can answer the
4 question yes or no. Do not reveal any
5 communications with counsel.

6 And we agree there's no waiver
7 associated with that answer, Counsel?

8 MR. LARIVEE: Yeah, I don't -- I
9 don't know how there could be, but I agree.

10 MS. HIGGINS: Okay.

11 A Yes.

12 Q (BY MR. LARIVEE) And you understand
13 that -- that Biofrontera has put forward certain
14 prior art that -- that they contend invalidates
15 the '028 patent, right? Again, I'm just looking
16 for a yes-or-no answer.

17 A Yes.

18 Q And before your deposition today did you
19 have any understanding that this Lundahl patent
20 was one of those prior art references?

21 A No.

22 Q Dr. Roberts, I'm showing you Figure 1 on

1 Exhibit 1014.

2 Do you have any sense of what is
3 being shown here?

4 MS. HIGGINS: Objection; form.
5 Lacks foundation.

6 A It shows a top-down view of patient's
7 head within a chamber.

8 Q (BY MR. LARIVÉE) And do you have a
9 sense of what that chamber is?

10 MS. HIGGINS: Objection; form.
11 Lacks foundation.

12 A Yeah. I mean, I couldn't say, because
13 there can be numerous devices with a chamber.

14 Q (BY MR. LARIVÉE) Dr. Roberts, what's
15 being shown in the image underneath Paragraph 33
16 here?

17 A So that's a photo that I took of the 3D
18 device that I use in my office.

19 Q And, Dr. Roberts, are the light sources
20 on the BLU-U device that you use in your office
21 uniformly distributed?

22 MS. HIGGINS: Objection; form.

1 Object to the extent it seeks claim construction
2 connected with this case.

3 A So looking at the picture, the three
4 center tubes are spaced equally. And I can't
5 really see the other one that would be
6 considered --

7 Q (BY MR. LARIVÉE) Let me see if I can --

8 A -- an orientation --

9 Q I'm sorry to interrupt you. Let me see
10 if I can offer you a more direct -- a different
11 picture from your declaration.

12 A Yeah. Right. So similarly in this
13 orientation of the box, the three central tubes
14 are equal distance apart. And you have a set of
15 two tubes. You have what would be the top in this
16 orientation and the bottom, and those are a little
17 bit closer together.

18 Q From -- from using your BLU-U for over
19 20 years, when you turn it on, Dr. Roberts, do you
20 notice any difference in the intensity of light
21 among the seven different fluorescent tubes there,
22 or are they all equal --

1 MS. HIGGINS: Objection; form.

2 MR. LARIVÉE: Could you let me
3 finish my question, please.

4 Q (BY MR. LARIVÉE) Or are they all equal
5 in brightness?

6 MS. HIGGINS: Objection; form.

7 A Well, the minute we turn on the device,
8 we all have goggles on. I'm not trying to stare
9 into this light. And so I close my eyes and, you
10 know, exit the room. So I'm not staring into the
11 chamber to see the intensity of the light.

12 Q (BY MR. LARIVÉE) You -- so you don't
13 know one way or another whether -- whether any of
14 the bulbs are brighter than the other?

15 A I just know my treatment results are
16 what I want.

17 Q Okay. I'm not asking about the
18 treatment results. And if -- if the answer to the
19 question is "I don't know," that's fine by me,
20 Dr. Roberts. But let's see if we can -- if I can
21 get an answer to the question I just asked.

22 Do you know one way or another

1 whether any of the bulbs are brighter than the
2 other?

3 MS. HIGGINS: Objection; form.
4 Asked and answered.

5 A Not that I'm aware of.

6 Q (BY MR. LARIVÉE) Dr. Roberts, I'm
7 directing your attention to Paragraph 35 and the
8 -- the picture contained in your -- in your report
9 beneath Paragraph 35.

10 Do you see that?

11 A Yes.

12 Q And if we see the very end of Paragraph
13 35 -- give me just a second -- that's referencing
14 Exhibit 2018, right?

15 A Yes.

16 Q And the text underneath the three photos
17 there says, "Positioning the BLU light -- BLU-U
18 light photodynamic therapy illuminator for
19 treatment."

20 Do you see that?

21 A Yes.

22 Q And so, Dr. Roberts, looking at that

1 center picture, we see the shape of the BLU-U,
2 right?

3 A Yes.

4 Q And you would agree that a -- a
5 layperson might -- might agree with me that the --
6 that the shape of the BLU-U is roughly a U shape,
7 correct?

8 MS. HIGGINS: Objection; form.
9 Calls for speculation.

10 Q (BY MR. LARIVÉE) Dr. Roberts, do you
11 need to speculate on the shape of the letter U?

12 MS. HIGGINS: You didn't ask about
13 her. Same objection.

14 A So when I look at this picture, I see a
15 U-shaped chamber, interior chamber.

16 Q (BY MR. LARIVÉE) And so there are --
17 there are two parallel straight portions, correct?

18 A Yes.

19 Q And a curved -- a curved portion
20 connecting those parallel straight portions,
21 correct?

22 A Correct.

1 Q Dr. Roberts, directing your attention to
2 the picture on the left here where we see the back
3 of the patient's head.

4 Do you see that picture?

5 A Yes.

6 Q And would you agree that the -- that the
7 straight portions of the U are -- are parallel to
8 the patient's -- roughly parallel to the sides of
9 the patient's head?

10 MS. HIGGINS: Objection; form.
11 Vague.

12 A The straight portions are parallel with
13 each other.

14 Q (BY MR. LARIVÉE) And in this picture
15 that we have here on the left, between those
16 parallel portions, do we see a patient's head?

17 A Yes, we do.

18 Q And you would agree with me that the --
19 the -- strike that.

20 Dr. Roberts, on the -- the left
21 photo and the center photo we're seeing two
22 different aspects of -- of the BLU-U device,

1 correct?

2 A Correct.

3 Q And in the center aspect we're seeing it
4 from -- in -- in a direction that -- that the U
5 shape goes around the top of the patient's skull.

6 Do you see that?

7 A Yes, I do.

8 Q And in the -- the left picture we see
9 that -- the BLU-U facing the patient's face.

10 Do you see that?

11 A Yes.

12 Q And my question for you is, which of the
13 -- of the dimensions of the illuminating area is
14 longer? Is it -- is it the center picture, or is
15 it the left picture?

16 MS. HIGGINS: Objection; form.

17 A The center of the illuminating area,
18 length, it's the same, because you've got the
19 center of the overleaning length just angled by 90
20 degrees one view to the other.

21 Q (BY MR. LARIVÉE) You know, let me see
22 if I can ask you a better question.

1 Dr. Roberts, we're seeing two -- in
2 the left and center picture we're seeing two
3 different aspects of a BLU-U device, right?

4 A Two different orientations.

5 Q Two different orientations. Understood.
6 Let's use that language.

7 We're seeing two different
8 orientations of the BLU-U device, right?

9 A Correct.

10 Q And the BLU-U device in the -- in the
11 left-hand picture we see a dimension beginning at
12 around the patient's shoulders and continuing to
13 the top of -- above the top of her head.

14 Do you see that dimension?

15 A Yes.

16 MS. HIGGINS: Objection; form.

17 Q (BY MR. LARIVÉE) And in -- and you
18 would agree that dimension has a length, correct?

19 A Correct.

20 Q And in the center picture we see a -- a
21 circumference for the interior of the U. We're
22 seeing that orientation, right?

1 MS. HIGGINS: Objection; form.

2 A Circumference is the entire edge of the
3 circle, so we're not seeing the entire
4 circumference.

5 Q (BY MR. LARIVÉE) Right. Let me see if
6 I can do better with my geometric terminology.

7 We are seeing in the center picture
8 a -- a linear dimension for the U, right?

9 MS. HIGGINS: Objection; form.

10 A If you mean a one-dimensional --

11 Q (BY MR. LARIVÉE) Yes.

12 A -- line, a one dimensional U-shaped
13 line?

14 Q Yes.

15 A Is that what you're asking me?

16 Q Yes.

17 MS. HIGGINS: Objection; form.

18 A Can you repeat your question?

19 Q (BY MR. LARIVÉE) We're seeing a
20 one-dimensional representation of a linear
21 dimension beginning at the patient's left shoulder
22 and continuing to his or her right shoulder,

1 correct?

2 MS. HIGGINS: Objection; form.

3 A I'm seeing -- I'm seeing that linear
4 dimension.

5 Q (BY MR. LARIVÉE) Okay. And my -- my
6 question to you, Dr. Roberts, is just, as someone
7 who has used the BLU-U, is the linear dimension of
8 the -- of the line from the -- in the left-hand
9 picture between the patient's shoulder and above
10 the top of her head longer or shorter than the
11 linear dim- -- dimension of the -- of the U-shaped
12 portion of the BLU-U shown in the center picture
13 on Page 12?

14 MS. HIGGINS: Objection; vague.
15 Lacks foundation.

16 A Can you repeat this question again?

17 Q (BY MR. LARIVÉE) Is the linear
18 dimension of the line in the left-hand picture
19 between the patient's shoulder and above the top
20 of her head longer or shorter than the linear
21 dimension of the U-shaped portion of the BLU-U
22 shown in the center picture on Page 12?

1 MS. HIGGINS: Objection; form.

2 A So it's like comparing apples to oranges
3 because you're comparing two different edges of
4 the machine that are rotated by 90 degrees.

5 Q (BY MR. LARIVÉE) Right.

6 And -- and I guess that is -- I
7 am -- I am telling you -- we would agree that --
8 that this -- this device has -- has different
9 edges, correct?

10 MS. HIGGINS: Objection; form.

11 A I would agree with that.

12 Q (BY MR. LARIVÉE) And the dimensions are
13 not the same along each of the edges, right?

14 MS. HIGGINS: Objection; form.

15 A I don't focus on the edges of the
16 machine, to be honest, so I'm not -- I'm having a
17 hard time answering this. That's not something I
18 focus on.

19 Q (BY MR. LARIVÉE) Dr. Roberts, on -- in
20 Paragraph 43 of your report, which I'm showing
21 here, you state that you have used the BLU-U
22 effectively to treat patients' faces, necks,

1 hands, arms, chest, and backs, correct?

2 A Correct.

3 Q And earlier you mentioned that you had
4 intended to include scalps in that list, correct?

5 A Correct.

6 Q And you -- you go on to state, "To treat
7 these areas, I simply position the device and the
8 patient appropriately."

9 A Uh-huh.

10 Q Do you see that?

11 A Yes, I do.

12 Q And what does it mean to position the --
13 the BLU-U appropriately?

14 A So for all treatments you want to make
15 sure that the body part that you're treating is
16 centered within the chamber of the device.

17 Q And you go on to cite in the next page
18 pictures from an instructional video that has been
19 marked as Exhibit 2018.

20 Do you see that?

21 A Yes.

22 Q And we see that here. And you would see

1 -- on the left you're seeing the patient's face,
2 correct?

3 MS. HIGGINS: Objection; form.

4 A I'm seeing a treatment of her face.

5 Q (BY MR. LARIVÉE) Thank you.

6 And in the center picture we see a
7 treatment of the scalp?

8 A Yes.

9 Q And in the right-hand picture you see a
10 picture of the hands, correct?

11 A Yes.

12 Q And when you're positioning to treat a
13 patient's face, how do you measure the distance
14 between the patient's face and the light-emitting
15 area of the -- of the BLU-U device?

16 MS. HIGGINS: Objection; form.
17 Lacks foundation.

18 A So when we position the device over the
19 patient, we make sure that the entire head is
20 within the chamber in the center of the chamber
21 and that the patient is centered in the middle and
22 that their nose is not touching the plastic liner

1 in front and that they're not moving their head to
2 either side.

3 So we're pretty much with them
4 centered within the chamber, and that's -- that's
5 how we do it. We don't take out a ruler and
6 measure. We can -- based on the training we've
7 had with the company and in the office with all
8 staff, we -- we've been instructed on how to
9 properly position the patient so that the area is
10 in the correct position for treatment.

11 Q (BY MR. LARIVÉE) Okay. Is -- is the
12 same true for when you position relative to the
13 scalp?

14 A So again, with the scalp we're going to
15 have them within the center of the chamber and
16 then, you know, just making sure that we've
17 cleared the back, like they're within the chamber
18 enough so the whole back section of their scalp is
19 going to be covered as well.

20 Q (BY MR. LARIVÉE) Okay. And how do you
21 position the hands within the BLU-U?

22 A So we use a Mayo stand, which is a metal

1 circular -- oh, I'm sorry, metal -- metal surgical
2 tray that you can wheel, and you can adjust the
3 height.

4 So typically the patient will be
5 sitting in a chair with their back to the wall,
6 and then we bring the Mayo stand in. And, you
7 know, there's an L-shaped base so it will clear
8 their feet. And we have them put their hands flat
9 on the stand with their fingers completely spread
10 apart so that we're, you know, exposing all the
11 areas on the back of the hands and the back of the
12 fingers. And then, again, we can change the
13 height of the -- the box so that the hands are
14 positioned within the middle of the chamber.

15 Q And do you use a ruler or any other
16 device to measure the treatment distance between
17 the hands and the -- the illuminator?

18 A No. We can just see that there's three
19 tubes in the center. If we center the hand with,
20 you know, the middle of the box, that we're, you
21 know, equidistance to the area that we need to be.

22 Q So the screenshots we see on -- in this

1 portion of your report and in Exhibit 2018 shown
2 here, they're only showing positioning of a
3 patient's face, neck, scalp, hands, and arms,
4 right?

5 A Correct.

6 Q And there's nothing here showing the --
7 the treatment of -- of a back, right?

8 A Correct.

9 Q Or a chest, right?

10 A Correct.

11 MR. LARIVEE: Okay. Can we please
12 have Exhibit 2018?

13 (Exhibit 2018 marked.)

14 Q (BY MR. LARIVEE) Dr. Roberts, I'm
15 showing you what has been marked as Exhibit 2018.

16 What is this document?

17 A This is a document from DUSA showing how
18 to use the LEVULAN KERASTICK with the BLU-U
19 device.

20 Q Okay. And I want to direct your
21 attention to the top of that page. There's a --
22 or actually, pardon me, I want to direct your

1 attention to the bottom center of that page that
2 says, "Captured by FireShot Pro: 25 November
3 2024," right?

4 Do you see that?

5 A Yes, I see that.

6 Q So that's when this -- this screenshot
7 was apparently captured, correct?

8 MS. HIGGINS: Objection; form.

9 You can answer if you know.

10 A I don't know.

11 Q (BY MR. LARIVÉE) Okay. Do you know
12 when this website was created?

13 A No.

14 Q Do you know whether -- one way or
15 another whether this website was created before or
16 after July 2024?

17 A I don't remember. I assume it was
18 before.

19 Q And what's the basis of that assumption?

20 A Because they've been around a long time,
21 so I imagine that they had these images.

22 Q Dr. Roberts, I'm just pulling in so we

1 can read the small text a bit better. I want to
2 direct your attention to the portion of the -- of
3 the website that says "Step 1," the paragraph and
4 the text underneath that.

5 Do you see that?

6 A Yes. Can you enlarge it?

7 Q Absolutely. How is that?

8 A Better. Thank you.

9 Q Could you just nod when you have --
10 you've had a chance to read that text?

11 A Okay. Okay.

12 Q And there's a portion here that says,
13 "Incubation Times: Face --

14 A Right.

15 Q -- or scalp: 14 to 18 hours."

16 Do you see that?

17 A Yes.

18 Q And with the 18 -- 14-to-18-hour
19 incubation time, is it your practice to apply the
20 LEVULAN to one of your patients one day and do the
21 treatment the next?

22 A So I have never used the 14-to-18-hour

1 incubation time. Anytime the LEVULAN is on the
2 skin for more than six hours, it gets into the
3 sheath around the nerve, and the patient will be
4 in exquisite agony while we do the treatment.

5 So I only know one person 20 years
6 ago who was a professor of mine at USC who tried
7 using that incubation time and came into the
8 clinic white as a sheet because he had a gentleman
9 in his office screaming as if he was being killed.
10 And so I don't know anybody since that time that
11 uses a 14-to-18-hour incubation.

12 Q How did you know not to use the
13 14-to-18-hour incubation time?

14 A Well, from that professor, but more
15 importantly when I bought my device I was trained
16 -- we were trained to do the 90-minute incubation,
17 how to do it.

18 Q Trained -- trained by the company?

19 A Yes.

20 Q Now let me zoom back out for a moment,
21 Dr. Roberts. I'm going to show you another page
22 on this exhibit.

1 A Okay.

2 Q I hope. I've apparently lost the
3 ability to zoom in or out. I've zoomed too hard.

4 THE REMOTE TECHNICIAN: Go -- I
5 mean, I can zoom out for you. But just go ahead
6 and re-click on the screen and see if -- does it
7 work for you now? I see you controlling the
8 mouse.

9 MR. LARIVEE: I -- I can't -- I
10 can't zoom out.

11 THE REMOTE TECHNICIAN: That's so
12 interesting. Okay. I'm assuming this is what you
13 want (indicating) full screen viewable?

14 MR. LARIVEE: Turn the edge to me.
15 Yeah, I don't have any control over -- over this.

16 THE REMOTE TECHNICIAN: That's so
17 interesting. You're moving the mouse. Here, I'll
18 take it down and put it back up. How about now
19 (indicating)?

20 MR. LARIVEE: Much better.

21 THE REMOTE TECHNICIAN: Okay.
22 Perfect.

1 MR. LARIVEE: I hope. Okay. Much
2 better.

3 Q (BY MR. LARIVEE) Dr. Roberts, I want to
4 direct your attention to Page 2 of Exhibit 2018.

5 What's being shown here?

6 A So this is a series of videos with a
7 little clip image of each one from the -- the
8 website.

9 Q Do you know when this video was created?

10 A No, I do not.

11 Q What -- what is the proper treatment
12 distance for the BLU-U according to the manual; do
13 you know?

14 MS. HIGGINS: Objection; form.
15 Outside the scope.

16 A I haven't looked at that manual for
17 years. I just go by the way we were trained.

18 Q (BY MR. LARIVEE) And how were you
19 trained?

20 A So we were trained to make sure that
21 when treating the face that the patient's head is
22 centered in the center of the chamber in all

1 dimensions and to make sure that the patient
2 doesn't, you know, move too close to the -- having
3 their head closer to one side or the other or
4 touching the inner plastic coating.

5 Q How is the neck treated if you're -- if
6 you're doing treatment on -- a photodynamic
7 therapy using the BLU-U?

8 A So if someone -- it's rare for someone
9 to just do a neck, because typically if they have
10 damage on their neck they have damage on their
11 face. So if we were going to treat both areas,
12 then typically they would use two KERASTICKS, one
13 for the face, one for the neck, to cover the full
14 surface area of both. And then we would -- if
15 they were small enough to be able to position the
16 device to be able to get full coverage of both
17 areas, we could use that with one session of the
18 16 minutes and 40 seconds of light.

19 And if we couldn't, then we'd cover
20 one area and then cover up the neck with a thick
21 terrycloth towel, we would treat the face. Then
22 we would cover the face with the thick terrycloth

1 towel and make sure that the towel was, you know,
2 tucked in behind the patient's head so that
3 there's no additional blue light being delivered.
4 And then we'd adjust the patient and the unit so
5 that it's now -- they'd typically be lying down,
6 and we would go around the full neck and we would
7 treat that area.

8 Q A moment ago you said, we'd use two
9 KERASTICKS, one for the face and one for the neck,
10 to cover the full surface area of both.

11 A Right.

12 Q What do you mean by that?

13 A To cover the entire region, the full
14 face or the full neck.

15 Q Okay. So you're -- you're covering the
16 -- the -- the entire face with LEVULAN using
17 the KERASTICK, correct?

18 A Yes. Yes.

19 Q And how did you know to do that?

20 A That's how we were trained.

21 Q By Sun Pharma?

22 A Yes. And that's what's in the

1 literature, and that makes biologic sense,
2 because, again, you know, you're not going to have
3 sun exposure to some one point, one dot on your
4 face, so that's the benefit of a treatment like
5 this.

6 Q I turn your attention to Paragraph 36.
7 Let me pull that up. Give me just a moment.

8 Dr. Roberts, if you could just nod
9 when you've had a chance to look at that
10 paragraph.

11 A Yes.

12 Q To treat the patient's chest or backs,
13 you've had patients turn in one direction so the
14 U-device wraps halfway around their chest or back,
15 right?

16 A So we have them seated on a chair, and
17 we then can wheel in the device to wrap around in
18 front of their -- the half, like in the center
19 point out to their shoulder and then around their
20 shoulders and then back to the center of their
21 back. And that's how we treat one side.

22 Then after that treatment is

1 completed, we either turn the patient, because
2 they're usually sitting on a chair, just like a
3 stool, so it doesn't have a back, so it's easy
4 enough for the patient to move versus the machine.
5 If the patient doesn't want to move, we can move
6 the machine around them. And then we do the same
7 thing. We position it from the center of their
8 chest, going around their shoulder, and to the
9 center of their back.

10 Q And -- and using that method, have you
11 been able to treat every patient for whom you've
12 wanted to treat their chest or back?

13 A So I can think of one patient during the
14 initial consultation that I didn't think was going
15 to be a good candidate for acne treatment. Those
16 are most of the patients that we're doing are acne
17 treatments. And because he was larger, I offered
18 him alternative therapies.

19 And when we do the consultation,
20 you know, we're screening for what we call
21 contraindications for every treatment. And so if
22 someone tells me they're claustrophobic or they've

1 had seizures or they get visual migraines, then
2 they're also turned away for light therapy.

3 Q So -- so the patient's size, either
4 because of obesity or because they're Dwayne "The
5 Rock" Johnson might be a contraindication for
6 fitting them within the BLU-U, right?

7 MS. HIGGINS: Objection; form.

8 A This is one patient out of 2,400
9 treatments. It's a low -- low number, extremely
10 low number.

11 Q (BY MR. LARIVEE) Okay.

12 MS. HIGGINS: Is this good time,
13 Counsel, we've been going over an hour, to take a
14 break?

15 MR. LARIVEE: Yeah, I think it's a
16 good time. And when we come -- you know, we can
17 take a 10-, 15-minute break. When we come back
18 from that break, I -- I don't think I have more
19 than half an hour, and probably less than half an
20 hour.

21 MS. HIGGINS: Okay. Good to know.

22 MR. LARIVEE: Okay.

1 MS. HIGGINS: We will take a
2 10-minute break. Is that sufficient?

3 THE WITNESS: Sure.

4 MS. HIGGINS: Okay. So 9:45 here.
5 We'll be back. We'll endeavor to be back.

6 MR. LARIVÉE: Okay. Thank you,
7 Counsel.

8 MS. HIGGINS: We're Pacific Time,
9 obviously, Brian.

10 MR. LARIVÉE: Yeah, I understand.
11 I'm on East Coast. James is Central. We're --
12 we're all over -- we're all over of the place.
13 We'll see you back at 12:45.

14 THE COURT REPORTER: Off the record
15 at 11:36 a.m.

16 (Break taken from 11:36 a.m. to
17 12:04 p.m.)

18 THE COURT REPORTER: We are back on
19 the record at 12:04 p.m.

20 Q (BY MR. LARIVÉE) Okay. Dr. Roberts,
21 during the break did you discuss any of the
22 substance of your testimony here today?

1 A No, I did not.

2 Q Did you discuss the possibility of a
3 redirect examination?

4 A No, I did not.

5 MR. LARIVEE: Okay. Could I please
6 have Exhibit 2015, Dr. Roberts' declaration, up on
7 the screen, Ms. Reif.

8 THE REMOTE TECHNICIAN: Absolutely.

9 Q (BY MR. LARIVEE) Dr. Roberts, I'm going
10 to direct you to Paragraph 34 on Page 13 of your
11 report, which begins here with what you're shown
12 and continues on to the next page. You might be
13 more comfortable using the paper copy.

14 Do you have that in front of you?

15 A Yes.

16 Q And here you state that the lighting
17 head of the BLU-U has --

18 A I'm sorry. Excuse me. There's a
19 missing -- oh, there it is.

20 Okay. Go ahead, I'm sorry.

21 Q Okay. You state that the lighting head
22 of the BLU-U has adjustable height positioning and

1 can be rotated to provide treatment flexibility to
2 a desired area, correct?

3 A Correct.

4 Q And what is treatment flexibility in
5 this context?

6 A Being able to adjust the box forward or
7 back, or up and down.

8 Q Okay. And you would agree that the
9 illuminator, itself, is not flexible, right?

10 A The actual U-shaped box?

11 Q Correct.

12 A Correct.

13 MR. LARIVÉE: Could we please have
14 Exhibit 2024 up on the screen.

15 (Exhibit 2024 marked.)

16 Q (BY MR. LARIVÉE) Dr. Roberts, I am
17 showing you what was marked as Exhibit 2024 on the
18 screen right now.

19 Do you recognize this document?

20 A Yes, I do.

21 Q And what is it?

22 A It's a picture of the BLU-U device and

1 with Labels 1, 2 and 3 describing features of
2 those sections of the box.

3 Q And is this Exhibit 2024 the same
4 exhibit cited in Paragraph 34 of your report?

5 A Yes, it is.

6 Q At the top of the page, there is a URL
7 web address for www.mydrugrep.com.

8 Do you see that?

9 A Yes.

10 Q What is mydrugrep.com?

11 MS. HIGGINS: Objection, form. To
12 the extent it calls for speculation.

13 A I'm not aware of that website.

14 Q (BY MR. LARIVÉE) How did you find this
15 website?

16 A I don't recall.

17 Q Do you know who created the content you
18 see in Exhibit 2024?

19 MS. HIGGINS: Objection, form.

20 A I mean, it's a picture of the DUSA
21 machine, and whether DUSA made that content or
22 somebody else, I don't know.

1 Q (BY MR. LARIVÉE) Do you know when the
2 content was created?

3 A No, I do not.

4 Q How does the BLU-U shown here provide
5 treatment flexibility?

6 MS. HIGGINS: Objection, form.

7 A Again, the ability to move the box up or
8 down, handle it forward and back to accommodate
9 different patients is what's meant by flexibility.

10 Q (BY MR. LARIVÉE) Okay. I want to show
11 you a portion on Page 2. Let me zoom in on this
12 and try not to break it.

13 Dr. Roberts, I'm directing you to
14 the paragraph beneath "Important Risk
15 Information." Could you please read that
16 paragraph and nod at me after you have had a
17 chance to read it?

18 A Okay.

19 Q And so it states that, quote:
20 "Application of LEVULAN KERASTICK should involve
21 either scalp or face lesions, but not both
22 simultaneously," unquote.

1 Do you see that?

2 A Yes, I do.

3 Q So it's not possible to treat the face
4 and scalp simultaneously?

5 MS. HIGGINS: Objection, form.
6 Calls for speculation.

7 A I mean, according to this document
8 they're warning against treating both scalp and
9 face -- scalp and the face at the same time.

10 Q (BY MR. LARIVÉE) And do you know why
11 that is?

12 MS. HIGGINS: Objection; form, to
13 the extent it calls for speculation.

14 A This is something it looks like from the
15 bottom of the page.

16 Could you scroll down to the bottom
17 of the page?

18 Yeah, this is in their operating
19 manual, so I wasn't involved with writing their
20 operating manual.

21 MR. LARIVÉE: Okay. Ms. Reif,
22 could I please have Exhibit 2049.

1 THE REMOTE TECHNICIAN: Stand by.

2 I'm just looking for it.

3 I'm not seeing a 2049. Let me see
4 if I missed it in the folder.

5 MR. LARIVEE: You may not have. I
6 can perhaps add it to the chat.

7 THE REMOTE TECHNICIAN: I would
8 appreciate that. I think it's just -- I think it
9 just wasn't uploaded.

10 MR. LARIVEE: Yeah, forgive us for
11 that.

12 THE REMOTE TECHNICIAN: That's
13 absolutely no problem. Do you know how to put a
14 document in the chat?

15 MR. LARIVEE: We're about to find
16 out.

17 THE REMOTE TECHNICIAN: It's just a
18 drag and drop.

19 MR. LARIVEE: Give me one moment.

20 THE REMOTE TECHNICIAN: Of course.

21 MR. LARIVEE: All right. That
22 should be going in the chat. Thanks for your

1 patience.

2 THE REMOTE TECHNICIAN: I'm
3 downloading it and I will put it up as soon as I
4 can.

5 It is on the screen.

6 (Exhibit 2049 marked.)

7 Q (BY MR. LARIVEE) Okay. Dr. Roberts,
8 could you please scroll through the document, and
9 my first question for you will be, what is this
10 document.

11 A This is my supplemental declaration.

12 MR. LARIVEE: All right.

13 Ms. Reif, when you have a moment
14 can I please have control of the document?

15 THE REMOTE TECHNICIAN: You have
16 it.

17 MR. LARIVEE: Thank you.

18 Q (BY MR. LARIVEE) Dr. Roberts, I'm just
19 directing your attention to Paragraph 7. And one
20 of the -- the second bullet down is information
21 regarding the RhodoLED XL and RhodoLED. Do you
22 see that?

1 A Yes I do.

2 Q And what information was that that you
3 were -- you considered?

4 A Basically, just that these two devices
5 exist, and looking at just the photos of them.

6 Q Okay. And there's pricing information
7 in there, you would agree, right?

8 A Yes, that is -- that was considered as
9 well. I apologize.

10 Q And where did you obtain the pricing
11 information?

12 A Pricing information, I obtained from
13 counsel.

14 Q Let me bring you down to Page 6. Here
15 it says that, quote, I understand that the current
16 market price for the RhodoLED XL is 18,500,
17 correct?

18 Do you see that?

19 A Correct. Yes, I see that.

20 Q Okay. And you go on, in the next
21 paragraph, to state that PDT devices like the
22 RhodoLED XL are large expenditures for dermatology

1 practices. Do you see that?

2 A Yes, I see that.

3 Q I'd like to understand, what is your
4 basis for claiming that 18,500 is a large
5 expenditure for a dermatology practice?

6 A My own personal experience in purchasing
7 devices.

8 Q And do you have a sense of what the
9 revenue of your practice was during 2024?

10 A Yes.

11 Q And what was the revenue of your
12 dermatology practice in 2024?

13 A I'm not going to share that.

14 MS. HIGGINS: And we don't have the
15 ability to go on a confidential record here,
16 Mr. Larivee, because you haven't provided for it,
17 so I'm just letting you know that.

18 MR. LARIVEE: Okay.

19 Q (BY MR. LARIVEE) Earlier you testified
20 that for a PDT treatment of actinic keratosis,
21 your treatment charge was \$800, correct?

22 A Around 800, yes.

1 Q And you testified that you've been using
2 the same PDT illuminator since 2004, correct?

3 A Correct.

4 Q And over that time, you've treated 2,400
5 patients with that illuminator, correct?

6 A Correct.

7 Q And so is it fair to say that you've
8 derived a significant amount of revenue from using
9 your PDT illuminator over the -- over of the
10 lifetime of its use?

11 MS. HIGGINS: Objection; form,
12 vague, lacks foundation.

13 A I mean, over the last 20 years prices
14 have gone up and overhead has gone up
15 tremendously, so I don't have the calculation in
16 front of me to tell you what the revenue generated
17 from that versus my increased overhead over the
18 last 20 years.

19 Q (BY MR. LARIVÉE) So you're saying your
20 prices for photodynamic therapy have increased
21 over the time in which you've held the device,
22 right?

1 A Correct. And the rising overhead of the
2 entire practice.

3 Q So even though you haven't had to buy a
4 new photodynamic illuminator, you could raise the
5 price for using that illuminator, correct?

6 MS. HIGGINS: Objection; calls for
7 speculation and hypothetical.

8 A All of the supplies, including the
9 LEVULAN stick, have gone up in price with
10 decreasing reimbursements over 20 years. So the
11 price for the actual treatment has to take all of
12 that into account, in addition to all the other
13 rising overhead costs, the staff, and everything
14 else that goes into running a practice.

15 Q (BY MR. LARIVÉE) I'm sorry, I asked I
16 think a fairly simple yes-or-no question. Is your
17 price for conducting photodynamic therapy of
18 actinic keratosis higher in 2025 than it was in
19 2024 [sic]?

20 A Yes. Oh, wait, 2025 versus twenty --
21 2004?

22 Q Yes. Let me let me ask my fairly simple

1 question again.

2 Is the price that you're charging
3 for photodynamic therapy of actinic keratosis
4 using the BLU-U higher in 2025 than it is when you
5 purchased the device in 2004?

6 A Yes.

7 Q Dr. Roberts, you state: "In my opinion,
8 an interested dermatology practice would not
9 purchase a more expensive PDT device unless there
10 were clear and significant benefits to the more
11 expensive device over the older device." Do you
12 see that?

13 A Yes, I do.

14 Q What types of significant benefits are
15 you -- do you have in mind in this sentence?

16 MS. HIGGINS: Objection; form,
17 calls for speculation.

18 A Having, you know, not reviewed all the
19 details of this device, I couldn't say.

20 Q (BY MR. LARIVÉE) Okay. So this is --
21 this is your declaration, right, Dr. Roberts?

22 A Correct.

1 Q And you chose the words "significant
2 benefits" here?

3 A Yes.

4 Q And so my question to you is, what do
5 you mean by "significant benefits"?

6 MS. HIGGINS: Same objection.

7 A So what I've stated is that in my
8 opinion, an interested dermatology practice. And
9 I'm not in that situation, so I couldn't speculate
10 on what benefits they would specifically be
11 looking for.

12 Q (BY MR. LARIVÉE) So you don't know what
13 benefits are intended by this -- by this sentence,
14 right?

15 A It is not a matter of not knowing what a
16 benefit could be. It's just, again, we have to do
17 a cost analysis and return on investment analysis
18 any time we buy new equipment.

19 So this sentence is just stating
20 that in my opinion, if a practice was interested
21 in purchasing a device and they already had a
22 device that could do the treatment, they would

1 want to have, you know, a significant reason for
2 doing so, for, you know, spending more money.

3 I mean, right now medicine, you
4 know, is in a very tight place just like the rest
5 of the economy. People are not looking to, you
6 know, buy more equipment if they don't need it.

7 Q Okay. You just used the phrase
8 "significant reason." What kind of reasons could
9 be a significant reason?

10 MS. HIGGINS: Objection; form,
11 calls for speculation.

12 A Again, I have not reviewed all the
13 details of the RhodoLED XL to give you a
14 significant reason.

15 Q (BY MR. LARIVÉE) How is treatment
16 efficacy of photodynamic therapy for -- of actinic
17 keratosis assessed?

18 A By me, personally?

19 Q By a dermatologist.

20 MS. HIGGINS: Objection; form,
21 overbroad, calls for speculation.

22 A So I can just speak for myself in my

1 practice, based on seeing the degree of reaction
2 after treatment, and then when I see the patient
3 for their follow-up one to three months, seeing
4 how many of their actinic keratosis are gone.

5 Q (BY MR. LARIVÉE) Okay. Is that called
6 a "clearance"?

7 MS. HIGGINS: Objection, form,
8 lacks foundation.

9 A I mean, clearance is a general term used
10 for, you know, everything from acne to rashes.
11 And so sometimes the patient comes in and
12 clinically looks clear, sometimes they, you know,
13 have an improvement by X percentage of their
14 condition. So, yes, if I see no active clinical
15 evidence of whatever problem they're coming in
16 for, then, yes, I would say that today they are
17 clear.

18 Q (BY MR. LARIVÉE) Now, you understand
19 that the FDA approved LEVULAN for use in
20 combination with the BLU-U illuminator, correct?

21 MS. HIGGINS: Objection; form,
22 calls for speculation.

1 A I mean, this is an FDA-approved
2 treatment for actinic keratosis.

3 Q And that FDA approved treatment is the
4 BLU-U illuminator in combination with LEVULAN,
5 correct?

6 MS. HIGGINS: Objection, form,
7 calls for speculation, outside the scope.

8 A Yeah, I don't know that I know that it's
9 specifically pairing it with the BLU-U device for
10 that FDA approval.

11 Q (BY MR. LARIVÉE) Give me just one
12 moment.

13 MR. LARIVÉE: Ms. Reif, could we
14 please have Exhibit 1022, the LEVULAN prescribing
15 information, up on the screen when you have a
16 moment?

17 THE REMOTE TECHNICIAN: Stand by.
18 (Exhibit 1022 marked.)

19 Q (BY MR. LARIVÉE) Dr. Roberts --

20 MS. HIGGINS: I'm sorry, can you
21 scroll -- can you scroll down to the bottom of the
22 document so we can see the exhibit number, please?

1 MR. LARIVEE: Sure.

2 MS. HIGGINS: You may have said
3 2022. Did you say 1022 or 2022?

4 MR. LARIVEE: I did say 1022.

5 MS. HIGGINS: Okay. Thank you.

6 MR. LARIVEE: Apologies, if I
7 misspoke.

8 Q (BY MR. LARIVEE) Dr. Roberts, I am
9 showing you Exhibit 1022, which is the highlights
10 of prescribing information for LEVULAN KERASTICK.

11 MS. HIGGINS: Objection to the
12 characterization.

13 Q (BY MR. LARIVEE) Have you seen this
14 document before?

15 A Can you scroll up and down to the top
16 and bottom of the document?

17 THE REMOTE TECHNICIAN: You have
18 control, Doctor.

19 MR. LARIVEE: Apparently, I
20 can't --

21 THE REMOTE TECHNICIAN: Oh, I can
22 give it to counsel. I --

1 THE WITNESS: Okay. Here. I've
2 got it.

3 THE REMOTE TECHNICIAN: I have
4 given control to the doctor. If that is
5 incorrect, let me know.

6 MS. HIGGINS: Can you read back the
7 question, please?

8 MR. LARIVÉE: I don't have
9 realtime.

10 MS. HIGGINS: Can the court
11 reporter read back the question, please.

12 (Requested portion read.)

13 A This looks like the drug insert that
14 comes with the LEVULAN KERASTICK.

15 Q (BY MR. LARIVÉE) Thank you. I'm going
16 to have a question for you on the Indications and
17 Usage paragraph.

18 A Okay.

19 Q And so my question is, is the LEVULAN
20 KERASTICK intended for use with the BLU-U
21 photolight -- photodynamic therapy illuminator?

22 MS. HIGGINS: And I am going to

1 object as outside the scope of this deposition,
2 and caution the witness not to speculate.

3 MR. LARIVEE: I mean, you can
4 object, Counsel, but you can't coach the witness,
5 please.

6 MS. HIGGINS: I'm not coaching the
7 witness. I'm objecting to your question as
8 outside the scope of this deposition and calling
9 for speculation.

10 A Under the Indications of Usage
11 paragraph --

12 Q (BY MR. LARIVEE) Uh-huh.

13 A -- they specifically mention the BLU-U
14 and blue light photodynamic therapy illuminator.

15 Q And so when a dermatologist makes a
16 decision to purchase a photodynamic illuminator,
17 would they consider the medication that it is
18 approved to be used with?

19 MS. HIGGINS: Objection; form,
20 overbroad.

21 A Well, they typically, when looking at
22 that technology, would also investigate what the

1 specific photosensitizer is because there's more
2 than -- there are other photosensitizers
3 available.

4 Q (BY MR. LARIVEE) And what would they do
5 to investigate the specific photosensitizer?

6 MS. HIGGINS: Objection; outside
7 the scope, overbroad.

8 A Speak to the company, read journal
9 articles, look at the promotional materials.

10 Q (BY MR. LARIVEE) And would they
11 consider the efficacy of the photosensitizer in
12 combination with the illuminator?

13 MS. HIGGINS: Objection; outside
14 the scope.

15 Counsel, I'm giving you a lot of
16 leeway here. This deposition is supposed to be
17 about the declaration submitted in this case per
18 the rules of this proceeding, and you're going way
19 outside the scope.

20 MR. LARIVEE: Well, you have a very
21 broad declaration about what a dermatologist would
22 do, and so this is perfectly within the scope of

1 Exhibit 2049, and I think your objections are
2 improper.

3 MS. HIGGINS: Okay. My objection
4 stands.

5 Can you read back the question?

6 Q (BY MR. LARIVÉE) Would a dermatologist
7 consider the efficacy of the photosensitizer in
8 combination with the illuminator when making a
9 decision on whether to purchase an illuminator?

10 MS. HIGGINS: Objection; overbroad,
11 scope.

12 A I mean, they would be looking at all
13 kinds of factors, so that would not be the only
14 factor.

15 Q (BY MR. LARIVÉE) Would that be a
16 factor?

17 MS. HIGGINS: Same objection.

18 A Yeah, I really can't speculate on that.

19 MR. LARIVÉE: Okay. Can we go off
20 the record for five minutes? I might be ready to
21 pass the witness, but give me just a minute.

22 I'll come back on the line at 45

1 past the hour.

2 THE COURT REPORTER: Off the record
3 at 12:40 p.m.

4 (Break taken from 12:40 p.m. to
5 12:50 p.m.)

6 THE COURT REPORTER: We are back on
7 the record at 12:50 p.m.

8 MR. LARIVÉE: Thank you,
9 Dr. Roberts. We would like to pass the witness.

10 MS. HIGGINS: Okay. Dr. Roberts, I
11 have a few questions for you as well.

12 CROSS-EXAMINATION

13 BY MS. HIGGINS:

14 Q So do you recall that earlier you
15 discussed trainings you received in connection
16 with the LEVULAN and the BLU-U -- the BLU-U? Do
17 you recall those discussions?

18 A Yes.

19 Q And you started receiving those
20 trainings over 20 years ago, right?

21 A Yes.

22 Q And you testified earlier that you also

1 reviewed research literature to determine on your
2 own as to how to use LEVULAN and BLU-U, right?

3 A Yes.

4 Q And not all of your trainings on LEVULAN
5 and BLU-U have been conducted by DUSA employees,
6 true?

7 A True.

8 MR. LARIVEE: Objection. You're
9 leading the witness.

10 Q (BY MS. HIGGINS) Let me rephrase the
11 question.

12 Have all of your trainings on
13 LEVULAN and BLU-U been conducted by DUSA
14 employees?

15 A No.

16 Q So you received training by people other
17 than DUSA employees on incubation time related to
18 LEVULAN and the BLU-U?

19 MR. LARIVEE: Objection; leading
20 the witness.

21 Q (BY MS. HIGGINS) You can answer the
22 question.

1 A Yes.

2 Q In your testimony earlier regarding
3 trainings relating to incubation time, you don't
4 know one way or another with certainty as to
5 whether those trainings were conducted by DUSA as
6 opposed to a third party; do you know that?

7 MR. LARIVEE: Objection; leading
8 the witness.

9 Q (BY MS. HIGGINS) Do you recall with
10 absolute certainty as to whether the trainings
11 relating to incubation time that you received were
12 conducted by DUSA?

13 MR. LARIVEEs: Objection; leading
14 the witness.

15 A Can you repeat the question?

16 Q (BY MS. HIGGINS) Sure.

17 Do you recall with absolutely
18 certainty as to whether the trainings related to
19 incubation time that you received were conducted
20 by DUSA?

21 MR. LARIVEE: Objection; leading
22 the witness.

1 A It was a long time ago, so I would have
2 to say no.

3 MS. HIGGINS: I have no further
4 questions at this time.

5 MR. LARIVEE: Give me one moment.

6 REDIRECT EXAMINATION

7 BY MR. LARIVEE:

8 Q During the last break, Dr. Roberts, did
9 you discuss the redirect with counsel?

10 A No, I did not.

11 MR. LARIVEE: Okay. No further
12 questions.

13 MS. HIGGINS: Okay. Court
14 Reporter, you had asked whether we had any
15 spellings or anything like that so when we --
16 earlier.

17 THE COURT REPORTER: Really quick.
18 Ms. Higgins, did you want to order a copy of the
19 transcript?

20 MS. HIGGINS: Yeah. We will take
21 the same time as our Polsinelli friends, so
22 whatever they're ordering, we'll do the same. I

1 think they have it on rush.

2 THE COURT REPORTER: And then
3 you'll receive it Monday. But did you want to
4 order a rough draft?

5 MS. HIGGINS: Yes. Sure. Thank
6 you.

7 THE COURT REPORTER: Off the record
8 at -- go ahead.

9 THE REMOTE TECHNICIAN: Sorry. I
10 just wanted to confirm, you guys want the exhibits
11 attached the same as last time?

12 MS. HIGGINS: We do not need any
13 exhibits attached.

14 THE REMOTE TECHNICIAN: For you,
15 sir, did you want them?

16 MR. LARIVEE: No exhibits attached.
17 No, thank you.

18 MS. HIGGINS: Yeah. And just to be
19 clear, the last time we didn't want the exhibits
20 attached either.

21 THE REMOTE TECHNICIAN: I just
22 misremembered. My apologies.

1 MS. HIGGINS: No worries.

2 THE COURT REPORTER: Off the record
3 at 12:55 p.m.

4 (End of proceedings at 12:55 p.m.)
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

CHANGES AND SIGNATURE

PAGE/LINE	CORRECTION	REASON FOR CHANGE
-----------	------------	-------------------

I, _____, have read the foregoing deposition and hereby affix my signature that same is true and correct except as noted herein.

STATE OF)
HEATHER J. ROBERTS, M.D.,
FAAD)

Subscribed and sworn to before me by the said witness, HEATHER J. ROBERTS, M.D., FAAD, on this the _____ day of _____, 2025.

NOTARY PUBLIC IN AND FOR
THE STATE OF

My Commission Expires: _____

1 I, Kelly Hassell, Certified Reporter and
2 Notary Public within and for the State of Texas
3 do hereby certify:

4 That HEATHER J. ROBERTS, M.D., FAAD, the
5 witness whose deposition is hereinbefore set
6 forth, was duly sworn by me before the
7 commencement of such deposition and that such
8 deposition was taken before me and is a true
9 record of the testimony given by such witness.

10 I further certify that the adverse party,
11 Sun Pharmaceutical Industries, Inc., was
12 represented by counsel at the deposition.

13 I further certify that the deposition of
14 HEATHER J. ROBERTS, M.D., FAAD, occurred in the
15 City of San Francisco, State of California, on the
16 25th of July, 2025, commencing at 9:07 a.m. CDT to
17 12:55 p.m.

18 I further certify that I am not related to
19 any of the parties to this action by blood or
20 marriage, I am not employed by or an attorney to
21 any of the parties to this action, and that I am
22 in no way interested, financially or otherwise, in

1 the outcome of this matter.

2
3
4 IN WITNESS WHEREOF, I have hereunto set my
5 hand this 27th day of July, 2025.
6
7
8
9

10 

11 KELLY HASSELL, CSR No. 5729
12 Cert. Expires 10/31/26
13 Planet Depos
14 Firm Registration No. 686
15 451 Hungerford Drive
Suite 400
Rockville, Maryland 20850
(888) 433-3767
16
17
18
19
20
21
22

A			
abilities	accordance	92:3	64:20, 69:15,
45:10	2:10	address	79:16, 83:14,
ability	according	32:15, 68:16,	84:12, 93:2,
18:20, 19:3,	90:12, 101:7	99:7	100:7, 108:1,
44:10, 89:3,	account	addressing	109:16, 110:12
100:7, 105:15	107:12	49:16	against
able	acetone	adjust	101:8
43:17, 43:22,	37:14	40:8, 40:13,	age
44:19, 53:13,	achieve	40:16, 40:18,	32:5
91:15, 91:16,	42:16	42:5, 43:17,	aging
94:11, 98:6	acid	43:22, 84:2,	47:10
about	25:22, 62:7,	92:4, 98:6	ago
11:18, 12:19,	62:11	adjustable	63:7, 88:6,
12:22, 14:12,	acne	45:12, 97:22	92:8, 118:20,
15:1, 17:10,	15:10, 15:22,	adjusted	121:1
17:15, 17:18,	58:10, 59:17,	41:10, 42:1	agony
17:21, 19:9,	59:22, 60:5,	adjustments	88:4
20:1, 20:8,	60:16, 94:15,	45:10	agree
25:13, 25:16,	94:16, 111:10	advance	33:1, 69:6,
25:17, 25:20,	actinic	6:18	69:9, 74:4,
26:6, 32:10,	35:5, 35:7,	adverse	74:5, 75:6,
39:15, 45:20,	37:4, 49:21,	125:10	75:18, 77:18,
47:7, 47:8,	50:3, 50:6,	aesthetic	80:7, 80:11,
52:1, 53:4,	50:11, 51:1,	15:20	98:8, 104:7
55:8, 58:19,	51:4, 51:21,	aestheticians	agreement
59:17, 60:13,	53:2, 53:12,	44:22	2:12
61:17, 72:17,	57:10, 58:10,	affect	ahead
74:12, 89:18,	58:13, 59:10,	49:14, 49:22	89:5, 97:20,
102:15, 116:17,	59:14, 62:4,	affix	122:8
116:21	105:20, 107:18,	124:14	aks
above	108:3, 110:16,	after	51:10, 52:2,
77:13, 79:9,	111:4, 112:2	10:21, 11:15,	52:10, 53:5
79:19	action	37:20, 37:22,	alcohol
above-styled	125:19, 125:21	38:3, 86:16,	37:13
2:6	active	93:22, 100:16,	all
abscesses	62:18, 111:14	111:2	17:5, 17:7,
29:14	actual	aftercare	17:18, 18:22,
absolute	98:10, 107:11	38:9, 38:10	19:4, 22:5,
120:10	actually	ag	32:15, 35:20,
absolutely	85:22	1:7	37:14, 38:21,
18:15, 28:6,	add	again	53:16, 56:7,
87:7, 97:8,	21:6, 21:14,	7:11, 8:8, 8:9,	58:5, 58:9,
102:13, 120:17	21:16, 21:21,	21:19, 23:1,	58:17, 61:4,
academic	102:6	37:3, 41:16,	71:22, 72:4,
28:22	addition	44:12, 48:6,	72:8, 81:14,
accommodate	107:12	48:19, 49:15,	83:7, 84:10,
100:8	additional	55:10, 56:21,	90:22, 96:12,
	38:7, 49:6,	60:19, 61:1,	102:21, 103:12,

107:8, 107:11, 107:12, 108:18, 110:12, 117:12, 119:4, 119:12 allows 43:19, 54:18 almost 35:1, 55:7 along 80:13 already 109:21 also 3:35, 20:11, 23:10, 32:5, 37:6, 52:21, 56:2, 95:2, 115:22, 118:22 alternative 94:18 always 35:12, 44:17, 50:4 ameluz 25:17, 25:20, 26:2, 26:5, 26:8, 26:12 aminolevulinic 25:22, 62:7, 62:11 among 71:21 amount 23:18, 56:3, 106:8 amplified 38:19 analysis 109:17 angeles 30:7 angled 76:19 another 6:6, 26:14, 32:15, 52:7, 72:13, 72:22, 86:15, 88:21,	120:4 answer 9:22, 10:1, 10:9, 10:16, 10:18, 11:17, 15:15, 16:20, 23:6, 25:7, 39:6, 47:2, 49:19, 50:21, 59:21, 62:13, 64:7, 64:21, 68:13, 69:3, 69:7, 69:16, 72:18, 72:21, 86:9, 119:21 answered 73:4 answering 9:9, 12:10, 80:17 answers 11:2 anticipate 6:4 any 6:8, 6:19, 10:7, 11:20, 12:4, 12:7, 12:21, 13:14, 14:7, 14:21, 16:6, 18:7, 19:22, 20:4, 20:5, 22:19, 23:12, 23:15, 23:20, 24:1, 24:6, 24:10, 24:11, 24:19, 24:22, 25:8, 25:12, 25:16, 27:10, 28:16, 28:19, 30:22, 40:11, 41:9, 49:13, 54:1, 63:16, 64:3, 64:11, 64:17, 64:21, 69:4, 69:19, 70:2, 71:20, 72:13,	73:1, 84:15, 89:15, 96:21, 109:18, 121:14, 122:12, 125:19, 125:21 anybody 88:10 anyone 14:18, 17:14 anything 29:22, 40:17, 41:20, 121:15 anytime 88:1 anywhere 38:6, 38:20 apart 71:14, 84:10 apologies 113:6, 122:22 apologize 6:18, 104:9 apparently 86:7, 89:2, 113:19 appeal 1:4 appearance 35:3, 35:9 appearances 4:2, 7:2 appears 19:21 apples 80:2 application 100:20 apply 37:15, 50:13, 60:5, 87:19 applying 60:9 appointments 29:1 appreciate 102:8 approached 17:21, 25:13,	25:17 appropriately 81:8, 81:13 approval 112:10 approved 111:19, 112:3, 115:18 approximately 52:17, 58:3, 59:7 area 21:19, 62:18, 76:13, 76:17, 82:15, 83:9, 84:21, 91:14, 91:20, 92:7, 92:10, 98:2 areas 11:16, 81:7, 84:11, 91:11, 91:17 arms 20:9, 21:3, 21:20, 81:1, 85:3 around 12:18, 17:1, 18:1, 36:21, 59:9, 59:15, 76:5, 77:12, 86:20, 88:3, 92:6, 93:14, 93:17, 93:19, 94:6, 94:8, 105:22 arriving 17:8 art 39:1, 39:12, 39:15, 69:2, 69:14, 69:20 articles 63:17, 116:9 aside 53:15 asked 72:21, 73:4,
---	---	---	---

Transcript of Heather J. Roberts, M.D., FAAD
Conducted on July 25, 2025

129

107:15, 121:14 asking 9:8, 66:5, 72:17, 78:15 aspect 76:3 aspects 75:22, 77:3 assessed 110:17 assignee 68:2 assistant 55:20 associate 29:3 associated 69:7 assume 57:7, 86:17 assuming 89:12 assumption 86:19 assumptions 64:4 attached 122:11, 122:13, 122:16, 122:20 attending 6:3 attendings 29:6 attention 22:8, 28:1, 31:19, 32:4, 35:22, 54:6, 63:20, 73:7, 75:1, 85:21, 86:1, 87:2, 90:4, 93:6, 103:19 attorney 10:17, 18:9, 125:20 attorneys 10:13, 17:15 available 56:5, 116:3	avenue 3:29 aware 6:6, 20:4, 24:21, 25:5, 26:2, 26:4, 73:5, 99:13 away 6:8, 23:9, 44:18, 58:22, 95:2 B back 20:9, 33:14, 39:16, 39:20, 46:17, 47:5, 50:6, 52:22, 54:4, 56:6, 67:10, 75:2, 83:17, 83:18, 84:5, 84:11, 85:7, 88:20, 89:18, 93:14, 93:20, 93:21, 94:3, 94:9, 94:12, 95:17, 96:5, 96:13, 96:18, 98:7, 100:8, 114:6, 114:11, 117:5, 117:22, 118:6 background 54:17 backs 21:4, 21:20, 81:1, 93:12 backup 6:7 base 84:7 based 83:6, 111:1 basically 37:12, 56:20, 104:4 basis 56:6, 86:19,	105:4 beauty 58:16 became 26:1, 26:4, 55:7 because 33:7, 34:21, 38:18, 41:16, 44:20, 48:6, 48:20, 48:21, 51:12, 52:21, 56:1, 61:4, 70:12, 76:18, 80:3, 86:20, 88:8, 91:9, 93:2, 94:1, 94:17, 95:4, 105:16, 116:1 become 25:4 been 8:3, 9:13, 9:14, 15:6, 20:2, 30:12, 30:18, 30:21, 30:22, 45:20, 57:21, 58:15, 59:5, 63:7, 65:10, 81:18, 83:8, 85:15, 86:20, 94:11, 95:13, 106:1, 119:5, 119:13 before 1:4, 2:8, 6:15, 9:1, 9:5, 9:22, 10:2, 10:9, 11:9, 12:14, 12:15, 13:20, 16:16, 16:18, 18:7, 18:11, 19:22, 25:13, 25:17, 25:21, 26:8, 26:11, 26:17, 65:15, 65:21, 66:6, 69:18, 86:15,	86:18, 113:14, 124:23, 125:6, 125:8 beginning 2:7, 50:21, 77:11, 78:21 begins 32:5, 36:2, 47:9, 97:11 behind 92:2 being 8:11, 8:20, 9:19, 12:9, 25:21, 31:8, 43:17, 44:19, 48:19, 50:5, 53:13, 58:19, 70:3, 70:15, 88:9, 90:5, 92:3, 98:6 belcher 3:36, 7:8, 14:17 believe 18:1, 54:14, 59:9, 59:14 below 20:13 beneath 73:9, 100:14 benefit 35:15, 37:6, 43:17, 93:4, 109:16 benefits 108:10, 108:14, 109:2, 109:5, 109:10, 109:13 benign 29:13 best 6:5 better 76:22, 78:6, 87:1, 87:8, 89:20, 90:2 between 25:5, 40:6,
--	---	--	---

61:5, 61:6, 75:15, 79:9, 79:19, 82:14, 84:16 bf-rhodoled 26:16, 26:17 big 38:11 billed 17:10 biochemical 54:19 biochemistry 54:18 biofrontera 1:6, 1:7, 7:4, 8:10, 24:7, 24:20, 25:5, 26:14, 69:13 biofrontera's 68:22 biologic 93:1 bioscience 1:6 bit 71:17, 87:1 blarivee@polsine- lli 3:8 blas 55:7 blood 48:8, 48:10, 48:12, 125:19 blu 73:17 blu-u 5:16, 5:18, 15:10, 15:19, 21:2, 38:2, 57:14, 57:18, 57:21, 58:6, 58:15, 58:16, 60:14, 62:1, 62:18, 63:8, 63:10, 67:2, 70:20, 71:18,	73:17, 74:1, 74:6, 75:22, 76:9, 77:3, 77:8, 77:10, 79:7, 79:12, 79:21, 80:21, 81:13, 82:15, 83:21, 85:18, 90:12, 91:7, 95:6, 97:17, 97:22, 98:22, 100:4, 108:4, 111:20, 112:4, 112:9, 114:20, 115:13, 118:16, 119:2, 119:5, 119:13, 119:18 blue 38:6, 38:7, 60:11, 60:18, 92:3, 115:14 board 1:4, 28:1, 28:16 body 81:15 boost 38:2 boston 3:6 both 34:9, 37:2, 55:15, 56:4, 91:11, 91:14, 91:16, 92:10, 100:21, 101:8 bottom 65:17, 71:16, 86:1, 101:15, 101:16, 112:21, 113:16 bought 59:8, 67:2, 67:5, 88:15 box 71:13, 84:13, 84:20, 98:6, 98:10, 99:2,	100:7 break 10:7, 10:10, 45:21, 46:12, 46:15, 46:20, 95:14, 95:17, 95:18, 96:2, 96:16, 96:21, 100:12, 118:4, 121:8 breaks 10:5, 30:22 brian 3:3, 7:3, 8:9, 96:9 bridget 3:36, 7:8, 14:16 briefly 22:21, 54:12, 56:18 brighter 35:10, 72:14, 73:1 brightness 72:5 bring 84:6, 104:14 broad 116:21 broadband 38:17 broken 32:12, 33:19, 34:5 brown 32:11, 33:19, 34:8, 41:5 bulbs 59:5, 72:14, 73:1 bullet 103:20 burn 45:3 burns 45:5 buy 45:16, 67:3,	67:6, 107:3, 109:18, 110:6 C ca 3:23 calculation 106:15 california 2:10, 3:21, 7:18, 34:22, 51:13, 125:15 call 38:1, 48:13, 94:20 called 13:2, 26:15, 30:8, 38:2, 68:7, 111:5 calling 115:8 calls 74:9, 99:12, 101:6, 101:13, 107:6, 108:17, 110:11, 110:21, 111:22, 112:7 calming 38:9 came 88:7 can't 45:18, 62:13, 63:4, 66:12, 71:4, 89:9, 89:10, 113:20, 115:4, 117:18 cancers 37:5 candidate 94:15 capillaries 32:12, 33:20, 34:5, 35:17 capped 23:19 captured 86:2, 86:7
---	---	--	--

care 54:20 careful 41:4, 58:20, 59:1 case 1:13, 12:19, 12:22, 13:1, 13:6, 13:11, 13:20, 15:1, 15:12, 17:6, 17:11, 17:15, 17:18, 17:22, 19:19, 22:11, 23:19, 25:14, 25:18, 25:21, 26:11, 26:17, 57:7, 68:22, 71:2, 116:17 cases 13:14, 13:16, 13:18, 55:6 cause 2:6, 56:22 caused 13:3 caution 12:20, 14:6, 15:15, 115:2 cautioned 8:3 cdt 2:8, 125:16 cedars-sinai 30:4 cell 50:5 cells 37:14, 57:2 center 71:4, 74:1, 75:21, 76:3, 76:14, 76:17, 76:19, 77:2, 77:20, 78:7, 79:12, 79:22, 82:6, 82:20, 83:15, 84:19,	86:1, 90:22, 93:18, 93:20, 94:7, 94:9 centered 81:16, 82:21, 83:4, 90:22 central 6:22, 71:13, 96:11 cert 126:13 certain 11:16, 69:13 certainty 120:4, 120:10, 120:18 certificate 4:9 certification 28:19 certifications 28:1, 28:16 certified 7:15, 125:1 certify 125:3, 125:10, 125:13, 125:18 chair 84:5, 93:16, 94:2 chamber 70:7, 70:9, 70:13, 72:11, 74:15, 81:16, 82:20, 83:4, 83:15, 83:17, 84:14, 90:22 chance 11:15, 50:5, 61:19, 87:10, 93:9, 100:17 change 84:12, 124:2 changes 11:4, 32:7, 32:15, 44:19, 124:1 characterization 113:12	charge 59:12, 59:18, 105:21 charging 108:2 chat 102:6, 102:14, 102:22 che 52:6 chemical 13:1, 13:3, 29:16, 51:7, 52:17, 53:1, 57:1 chemo 52:6, 52:11 chemotherapy 51:6, 52:15 chest 20:9, 81:1, 85:9, 93:12, 93:14, 94:8, 94:12 chests 21:3, 21:20 choose 45:11, 53:9 chose 62:14, 109:1 circle 78:3 circled 53:18 circular 84:1 circumference 77:21, 78:2, 78:4 cite 16:7, 81:17 cited 99:4 city 125:15 civil 2:11 claim 71:1	claiming 105:4 clarity 4:12 claustrophobic 94:22 cleanse 37:13 clear 8:16, 10:19, 10:20, 17:9, 66:4, 67:11, 84:7, 108:10, 111:12, 111:17, 122:19 clearance 111:6, 111:9 cleared 83:17 click 19:1 clinic 29:6, 88:8 clinical 29:2, 111:14 clinically 21:2, 111:12 clip 90:7 close 72:9, 91:2 closer 71:17, 91:3 clr 2:9 co2 29:19, 53:6 coach 115:4 coaching 115:6 coast 96:11 coating 91:4 color 41:19 com 3:8, 3:16,
--	--	--	---

3:25, 3:33, 99:7, 99:10 combination 37:3, 62:2, 111:20, 112:4, 116:12, 117:8 come 39:16, 48:12, 48:22, 55:20, 60:11, 60:18, 68:19, 95:16, 95:17, 117:22 comes 32:5, 35:2, 40:1, 53:12, 68:13, 111:11, 114:14 comfortable 97:13 coming 30:1, 50:6, 60:21, 111:15 commencement 125:7 commencing 125:16 comment 45:18, 66:12 commission 124:30 common 51:6 communications 14:7, 15:17, 25:9, 64:8, 64:22, 69:5 companies 44:15, 44:16 company 83:7, 88:18, 116:8 compared 35:20, 36:10, 45:7, 53:10, 58:16 comparing 80:2, 80:3 compensated 22:9	compensation 23:11, 23:15, 23:18 completed 94:1 completely 84:9 compliance 53:11 complications 45:5 complimentary 6:16 computer 6:9 concentration 62:11 concerning 24:2, 24:7 concerns 68:22 condition 12:8, 111:14 conditions 58:11 conduct 58:5, 59:10, 59:16 conducted 58:3, 119:5, 119:13, 120:5, 120:12, 120:19 conducting 39:2, 107:17 conferences 26:7, 56:4 confidential 12:21, 23:2, 105:15 confirm 57:9, 122:10 connect 6:13 connected 71:2 connecting 6:14, 74:20 connection 64:12, 64:16,	68:6, 118:15 consider 10:15, 54:9, 64:18, 115:17, 116:11, 117:7 considered 63:21, 64:14, 71:6, 104:3, 104:8 constantly 55:22 construction 71:1 consultant 44:16 consultation 94:14, 94:19 consultations 35:12 consulting 22:19, 22:22, 23:8 contact 18:8 contacted 25:10 contained 73:8 contains 11:1, 62:6 contend 69:14 content 99:17, 99:21, 100:2 contention 69:1 context 98:5 continues 97:12 continuing 77:12, 78:22 continuous 30:21 contraindication 95:5 contraindications 94:21	control 11:13, 22:2, 22:4, 27:17, 28:10, 31:21, 53:16, 56:13, 65:7, 66:15, 89:15, 103:14, 113:18, 114:4 controlling 89:7 conversations 6:10 cooling 42:7, 42:8, 42:10, 42:11 copies 11:22 copy 19:11, 19:13, 19:18, 27:7, 28:4, 28:10, 28:11, 28:13, 31:12, 65:17, 65:22, 97:13, 121:18 corporation 30:10, 30:13 correct 9:3, 9:4, 16:17, 19:13, 19:18, 21:7, 22:14, 22:15, 23:14, 30:17, 33:22, 34:12, 43:11, 43:13, 43:15, 57:15, 57:22, 58:1, 58:3, 58:4, 62:5, 68:7, 68:8, 74:7, 74:17, 74:21, 74:22, 76:1, 76:2, 77:9, 77:18, 77:19, 79:1, 80:9, 81:1, 81:2, 81:4, 81:5, 82:2, 82:10,
--	--	---	--

83:10, 85:5, 85:8, 85:10, 86:7, 92:17, 98:2, 98:3, 98:11, 98:12, 104:17, 104:19, 105:21, 106:2, 106:3, 106:5, 106:6, 107:1, 107:5, 108:22, 111:20, 112:5, 124:15 correction 21:5, 124:2 corrections 4:8, 20:5 correspond 41:18, 42:13 corresponds 41:20, 42:15 cosmetic 32:19, 33:3, 34:1, 34:2, 34:3, 34:4, 34:5, 34:6, 34:8, 34:18, 35:13, 35:20, 35:21, 37:6 cost 59:8, 109:17 costs 107:13 could 7:1, 7:19, 12:1, 18:12, 18:13, 20:16, 20:17, 22:1, 22:21, 26:20, 28:10, 31:3, 31:20, 43:9, 47:4, 47:11, 54:3, 54:12, 56:11, 56:12, 56:18, 65:2, 66:14, 67:9, 67:16, 67:17, 69:9, 72:2, 87:9, 91:17,	93:8, 97:5, 98:13, 100:15, 101:16, 101:22, 103:8, 107:4, 109:16, 109:22, 110:8, 112:13 couldn't 70:12, 91:19, 108:19, 109:9 counsel 5:2, 7:1, 8:12, 14:8, 14:9, 14:12, 15:17, 16:12, 16:14, 19:15, 25:9, 46:1, 46:21, 64:9, 64:22, 66:4, 68:13, 68:17, 69:5, 69:7, 95:13, 96:7, 104:13, 113:22, 115:4, 116:15, 121:9, 125:12 count 33:20 county 55:4 couple 19:8, 31:16, 61:16 course 102:20 court 6:21, 7:12, 7:14, 7:22, 9:16, 9:18, 10:22, 14:2, 42:9, 46:13, 46:17, 96:14, 96:18, 114:10, 118:2, 118:6, 121:13, 121:17, 122:2, 122:7, 123:2 cover 42:18, 91:13, 91:19, 91:20,	91:22, 92:10, 92:13 coverage 91:16 covered 83:19 covering 92:15 covers 29:20, 62:18 crazy 48:11 cream 38:10 creams 53:19 created 38:1, 86:12, 86:15, 90:9, 99:17, 100:2 cross-examination 4:6, 118:12 crusted 50:10 cryotherapy 42:7, 51:5, 51:22, 52:3 csr 2:9, 7:18, 126:12 current 44:20, 59:14, 104:15 curriculum 5:12, 27:7 cursorry 16:4 curved 74:19 customizations 45:9 customize 43:19 cutaneous 29:12 cutoff 40:18, 40:20, 41:2, 41:7	D dallas 7:16 damage 34:22, 35:1, 35:2, 91:10 darker-skinned 41:3, 41:8 data 64:18 date 10:15 day 2:7, 10:6, 35:2, 87:20, 124:25, 126:5 dealing 55:10 debridement 50:14 december 17:1, 61:7 decision 115:16, 117:9 declaration 5:9, 5:21, 14:10, 16:3, 16:7, 19:6, 19:16, 19:19, 20:3, 20:5, 20:8, 21:10, 55:14, 56:15, 61:21, 62:16, 64:3, 64:13, 64:17, 64:19, 71:11, 97:6, 103:11, 108:21, 116:17, 116:21 declarations 11:22 decreasing 107:10 deep 45:17, 51:7, 52:17, 53:1 deeper 32:11, 33:18,
--	---	---	---

34:3, 54:18 definitely 51:13 definition 38:17, 38:18, 48:1 degrease 37:13 degree 54:17, 111:1 degrees 76:20, 80:4 delight 32:20 delivered 92:3 dependent 23:12, 23:16 depending 37:21, 38:4, 60:19 depends 44:12 depos 126:14 deposed 8:20 deposition 1:20, 2:3, 6:17, 9:7, 10:21, 11:8, 12:14, 12:17, 14:1, 14:5, 16:13, 16:17, 16:19, 17:8, 46:21, 69:18, 115:1, 115:8, 116:16, 124:14, 125:5, 125:7, 125:8, 125:12, 125:13 depth 42:15, 49:9, 49:21, 50:9 derived 106:8 dermabrasion 29:18	dermatologic 29:8, 55:2 dermatological 29:10 dermatologist 43:16, 43:22, 45:7, 110:19, 115:15, 116:21, 117:6 dermatology 29:3, 29:7, 54:11, 54:15, 54:22, 55:3, 56:9, 57:14, 104:22, 105:5, 105:12, 108:8, 109:8 describe 22:21, 23:5, 54:12 describing 99:1 description 5:3 desired 98:2 desmarais 3:20, 3:28, 3:36, 7:7, 8:15, 17:21, 18:8, 25:10, 64:4 destroy 57:1 details 108:19, 110:13 determine 49:9, 119:1 developing 44:17 device 36:9, 40:2, 57:14, 58:15, 59:4, 59:8, 62:2, 63:8, 63:10, 63:14, 65:19, 70:18, 70:20, 72:7, 75:22, 77:3,	77:8, 77:10, 80:8, 81:7, 81:16, 82:15, 82:18, 84:16, 85:19, 88:15, 91:16, 93:17, 98:22, 106:21, 108:5, 108:9, 108:11, 108:19, 109:21, 109:22, 112:9 devices 36:14, 38:21, 38:22, 42:4, 44:9, 44:10, 58:17, 70:13, 104:4, 104:21, 105:7 diagnosis 57:4, 57:7 diagram 53:18, 65:16, 65:21 die 49:4 difference 71:20 different 33:20, 44:8, 48:3, 50:17, 60:7, 68:19, 71:10, 71:21, 75:22, 77:3, 77:4, 77:5, 77:7, 80:3, 80:8, 100:9 dim 79:11 dimension 77:11, 77:14, 77:18, 78:8, 78:21, 79:4, 79:7, 79:11, 79:18, 79:21 dimensional 78:12 dimensions 76:13, 80:12,	91:1 diminished 35:5 direct 4:5, 4:12, 8:6, 11:16, 20:17, 22:8, 31:18, 35:22, 54:6, 71:10, 85:20, 85:22, 87:2, 90:4, 97:10 directing 28:1, 32:4, 63:20, 73:7, 75:1, 100:13, 103:19 direction 76:4, 93:13 directly 63:3 disagree 33:5 discuss 46:20, 96:21, 97:2, 121:9 discussed 118:15 discussions 6:8, 118:17 diseases 55:2, 55:8 dispute 25:5 distance 71:14, 82:13, 84:16, 90:12 distributed 70:21 dive 45:17 doctor 7:13, 27:17, 65:6, 113:18, 114:4 document 11:16, 11:18, 19:7, 20:1, 22:2, 22:9,
--	--	---	---

27:6, 27:8, 27:12, 31:11, 31:21, 56:13, 65:15, 66:5, 66:10, 66:15, 85:16, 85:17, 98:19, 101:7, 102:14, 103:8, 103:10, 103:14, 112:22, 113:14, 113:16 documents 11:20, 14:10, 14:21, 15:12, 15:18 doing 33:10, 48:7, 48:20, 52:12, 54:21, 55:3, 60:8, 61:3, 61:9, 91:6, 94:16, 110:2 done 15:7, 17:5, 17:8, 19:8, 37:7, 37:8, 38:3, 49:1, 53:1, 53:21 dot 93:3 down 9:19, 26:21, 27:15, 28:22, 44:18, 47:8, 53:15, 57:17, 66:18, 66:19, 67:20, 89:18, 92:5, 98:7, 100:8, 101:16, 103:20, 104:14, 112:21, 113:15 downloading 103:3 dr 3:36, 5:13, 7:8, 8:8, 8:19, 12:4, 12:7, 12:13, 15:9,	15:11, 15:20, 16:2, 16:9, 17:20, 18:18, 19:5, 19:17, 21:9, 22:7, 25:4, 25:12, 27:4, 27:22, 28:15, 30:3, 30:11, 31:7, 32:3, 46:19, 47:6, 50:20, 53:22, 54:5, 54:8, 56:14, 58:5, 61:16, 61:22, 63:6, 63:19, 65:9, 65:14, 66:21, 68:1, 68:5, 68:20, 69:22, 70:14, 70:19, 71:19, 72:20, 73:6, 73:22, 74:10, 75:1, 75:20, 77:1, 79:6, 80:19, 85:14, 86:22, 88:21, 90:3, 93:8, 96:20, 97:6, 97:9, 98:16, 100:13, 103:7, 103:18, 108:7, 108:21, 112:19, 113:8, 118:9, 118:10, 121:8 draft 122:4 drag 102:18 drainage 29:14 drive 126:16 driving 48:11 drop 102:18 drug 114:13	duly 7:21, 8:3, 125:6 dummy 44:18 duration 40:16, 42:6, 44:4 during 14:14, 14:22, 46:20, 59:3, 94:13, 96:21, 105:9, 121:8 dusa 66:22, 67:3, 67:6, 68:3, 85:17, 99:20, 99:21, 119:5, 119:13, 119:17, 120:5, 120:12, 120:20 dwayne 95:4 dye 29:18, 41:15 E each 6:15, 9:21, 75:13, 80:13, 90:7 earlier 81:3, 105:19, 118:14, 118:22, 120:2, 121:16 early 51:16, 61:2, 61:7 easier 28:5 east 96:11 easy 94:3 economy 110:5 edge 78:2, 89:14	edges 80:3, 80:9, 80:13, 80:15 education 27:11, 54:13, 56:2 educational 26:6 effect 9:15 effective 21:2, 53:14 effectively 80:22 effects 37:10 efficacy 110:16, 116:11, 117:7 ehrenreich 16:9 ehrenreich's 16:2 either 61:6, 83:2, 94:1, 95:3, 100:21, 122:20 else 14:18, 29:22, 40:17, 99:22, 107:14 emerges 34:15 emitting 38:14 employed 125:20 employees 119:5, 119:14, 119:17 employment 27:11, 30:19, 30:21 enabled 6:11 end 45:4, 73:12, 123:4
--	--	---	---

endeavor 96:5 enlarge 87:6 enough 50:19, 83:18, 91:15, 94:4 entire 37:15, 78:2, 78:3, 82:19, 92:13, 92:16, 107:2 entitled 31:8 environment 44:20 equal 71:14, 71:22, 72:4 equally 71:4 equidistance 84:21 equipment 59:2, 109:18, 110:6 errors 20:4 esq 3:3, 3:10, 3:19, 3:27 europe 36:19 even 10:16, 35:11, 38:22, 50:8, 107:3 eventually 56:5 ever 12:13, 13:19, 14:1, 26:8, 26:11, 26:12, 26:16, 49:3, 55:13, 66:5 every 35:2, 50:2, 50:22, 94:11,	94:21 everybody 48:22 everyone 6:3 everything 9:19, 107:13, 111:10 evidence 111:15 examination 4:5, 4:7, 8:6, 97:3, 121:6 except 124:15 excisions 29:12 excuse 97:18 exhibit 4:4, 5:3, 5:4, 5:7, 5:9, 5:12, 5:15, 5:17, 5:18, 5:21, 11:13, 18:14, 18:17, 18:19, 18:21, 19:5, 19:12, 19:18, 26:21, 26:22, 27:3, 27:5, 28:4, 31:4, 31:6, 31:8, 31:9, 31:15, 47:5, 53:21, 54:4, 65:3, 65:5, 65:10, 67:12, 67:20, 70:1, 73:14, 81:19, 85:1, 85:12, 85:13, 85:15, 88:22, 90:4, 97:6, 98:14, 98:15, 98:17, 99:3, 99:4, 99:18, 101:22, 103:6, 112:14, 112:18, 112:22, 113:9,	117:1 exhibits 5:1, 11:9, 16:6, 122:10, 122:13, 122:16, 122:19 exist 104:5 exit 72:10 expenditure 105:5 expenditures 104:22 expensive 108:9, 108:11 experience 30:4, 54:13, 56:16, 105:6 experiences 55:16 expert 13:11, 13:13, 13:17, 13:19, 17:22, 22:10, 23:22, 24:5, 25:14, 25:18, 25:21, 54:10, 54:15, 56:9 expertise 27:13, 44:14 expires 124:30, 126:13 explain 56:18, 57:3 explains 62:1 exposing 84:10 exposure 13:1, 13:3, 49:8, 60:6, 93:3 expressed 64:5, 64:19 exquisite 88:4 extent 71:1, 99:12,	101:13 extra 50:13 extremely 95:9 eyes 72:9 F faad 1:21, 2:4, 5:11, 5:23, 8:2, 124:20, 124:24, 125:4, 125:14 face 20:9, 21:19, 34:14, 35:15, 37:3, 37:13, 37:16, 76:9, 82:1, 82:4, 82:13, 82:14, 85:3, 87:13, 90:21, 91:11, 91:13, 91:21, 91:22, 92:9, 92:14, 92:16, 93:4, 100:21, 101:3, 101:9 faces 21:3, 21:20, 80:22 facility 55:4, 55:12 facing 76:9 fact 36:19, 44:15 factor 117:14, 117:16 factors 49:13, 117:13 facts 64:17 fair 106:7 fairly 107:16, 107:22 fall 51:16
---	--	--	---

familiar 38:13 fda 111:19, 112:3, 112:10 fda-approved 112:1 features 99:1 fee 59:14 feel 10:6, 31:14, 56:7 feet 84:8 few 20:2, 63:6, 118:11 field 54:9 figure 65:13, 66:2, 69:22 figures 66:10 filter 40:18, 40:20, 41:2 finally 11:7 financial 24:10, 24:11 financially 125:22 find 99:14, 102:15 fine 11:19, 19:15, 28:7, 32:10, 33:18, 34:1, 35:16, 46:9, 72:19 fingers 84:9, 84:12 finish 9:22, 10:1, 72:3	fireshot 86:2 firm 7:7, 18:8, 126:15 first 8:3, 9:8, 19:19, 21:1, 25:4, 26:1, 26:4, 28:2, 32:4, 35:12, 50:15, 52:18, 57:18, 63:11, 65:9, 65:14, 103:9 fitting 95:6 five 33:20, 46:1, 46:7, 46:9, 117:20 five-part 15:21 flat 84:8 flexibility 44:19, 45:3, 98:1, 98:4, 100:5, 100:9 flexible 98:9 floor 3:30 floppy 38:12 fluence 40:6, 40:9, 42:6, 44:4 fluent 63:10, 63:13 fluorescent 59:4, 71:21 focus 33:2, 80:15, 80:18 focused 33:7 folder 102:4	follow-up 111:3 follows 8:5 foregoing 124:14 forever 49:1 forgive 62:9, 102:10 form 25:22, 39:4, 41:1, 42:14, 44:5, 45:13, 47:17, 50:1, 57:5, 59:13, 62:12, 63:12, 70:4, 70:10, 70:22, 72:1, 72:6, 73:3, 74:8, 75:10, 76:16, 77:16, 78:1, 78:9, 78:17, 79:2, 80:1, 80:10, 80:14, 82:3, 82:16, 86:8, 90:14, 95:7, 99:11, 99:19, 100:6, 101:5, 101:12, 106:11, 108:16, 110:10, 110:20, 111:7, 111:21, 112:6, 115:19 formally 18:3 forming 64:5, 64:18 forth 2:12, 125:6 forward 69:13, 98:6, 100:8 foundation 39:5, 42:3, 55:11, 70:5, 70:11, 79:15,	82:17, 106:12, 111:8 founded 30:15 four 60:21 frame 39:3 francisco 2:10, 3:23, 7:17, 125:15 free 31:14 friends 121:21 front 19:12, 28:4, 28:13, 83:1, 93:18, 97:14, 106:16 full 12:1, 12:3, 37:3, 38:3, 38:20, 89:13, 91:13, 91:16, 92:6, 92:10, 92:13, 92:14 full-face 48:8 fully 12:11 further 121:3, 121:11, 125:10, 125:13, 125:18 future 49:6
G			
gabrielle 3:19, 7:6, 14:16 gaps 30:22 general 15:3, 15:5, 68:14, 111:9 generally 15:11, 15:16,			

23:5, 43:21 generated 106:16 gentleman 88:8 geometric 78:6 getting 38:20, 39:8, 50:19, 53:17, 61:14 ghiggins@desmara- isllp 3:25 giant 38:11 give 11:13, 13:2, 38:6, 38:8, 38:11, 45:3, 53:13, 73:13, 93:7, 102:19, 110:13, 112:11, 113:22, 117:21, 121:5 given 65:18, 66:1, 114:4, 125:9 gives 55:1 giving 33:7, 33:11, 53:17, 116:15 glow 35:10 gmbh 1:6, 1:7 go 9:7, 36:20, 39:20, 55:19, 56:5, 81:6, 81:17, 89:4, 89:5, 90:17, 92:6, 97:20, 104:20, 105:15, 117:19, 122:8 goes 32:10, 40:4,	40:5, 76:5, 107:14 goggles 72:8 going 9:8, 9:9, 15:14, 23:9, 31:15, 35:8, 35:9, 35:10, 40:5, 45:20, 47:1, 49:3, 50:15, 56:11, 65:12, 68:11, 68:16, 83:14, 83:19, 88:21, 91:11, 93:2, 94:8, 94:14, 95:13, 97:9, 102:22, 105:13, 114:15, 114:22, 116:18 gold 15:9, 15:20 gone 48:9, 106:14, 107:9, 111:4 good 7:10, 8:8, 45:20, 94:15, 95:12, 95:16, 95:21 graduated 55:7 graduating 55:9 great 46:11 grow 34:14 growths 29:13 guess 49:20, 51:2, 80:6 guys 122:10 H habbaz 3:27, 7:8	hair 29:14 half 93:18, 95:19 halfway 93:14 hand 7:19, 84:19, 126:5 handle 100:8 hands 20:9, 21:3, 21:20, 81:1, 82:10, 83:21, 84:8, 84:11, 84:13, 84:17, 85:3 hang 20:19 happy 45:22, 46:12 hard 19:11, 19:13, 28:4, 28:9, 28:13, 80:17, 89:3 hassell 2:8, 7:15, 125:1, 126:12 hat 38:12 hci 62:7 hcl 62:8 head 20:13, 20:14, 65:18, 70:7, 75:3, 75:9, 75:16, 77:13, 79:10, 79:20, 82:19, 83:1, 90:21, 91:3, 92:2, 97:17, 97:21 healthy 34:15	heard 26:16, 57:6 hearing 26:6 heather 1:21, 2:4, 5:10, 5:22, 8:2, 12:3, 30:9, 30:12, 124:19, 124:24, 125:4, 125:14 height 84:3, 84:13, 97:22 held 106:21 help 6:12, 9:6 helpful 43:21 helps 41:2 here 9:19, 17:8, 20:1, 27:14, 28:17, 32:5, 33:1, 33:6, 48:5, 48:14, 48:16, 57:13, 64:3, 68:2, 70:3, 70:16, 75:2, 75:15, 80:21, 81:22, 85:2, 85:6, 87:12, 89:17, 90:5, 96:4, 96:22, 97:11, 97:16, 100:4, 104:14, 105:15, 109:2, 114:1, 116:16 hereby 124:14, 125:3 herein 124:16 hereinafter 2:12 hereinbefore 125:5
---	--	--	---

hereunto 126:4 hesitating 47:22 higher 107:18, 108:4 highlights 5:7, 113:9 holidays 61:6 home 53:19 honest 80:16 hope 89:2, 90:1 hoping 55:19 hormonal 32:7 hormonally-induced 41:6 hour 22:10, 45:20, 95:13, 95:19, 95:20, 118:1 hourly 22:10 hours 14:13, 16:12, 17:4, 17:10, 87:15, 88:2 houston 3:14 however 10:8 huge 53:11 hungerford 126:16 hyperkeratotic 50:11 hypothetical 45:15, 107:7 I identify 6:12, 6:14,	12:22 illuminating 76:13, 76:17 illuminator 26:15, 73:18, 84:17, 98:9, 106:2, 106:5, 106:9, 107:4, 107:5, 111:20, 112:4, 114:21, 115:14, 115:16, 116:12, 117:8, 117:9 image 70:15, 90:7 images 86:21 imagine 86:21 immune 51:6 immunotherapy 52:15 impact 41:4 important 9:20, 100:14 importantly 88:15 improper 117:2 improvement 35:16, 35:17, 49:17, 111:13 improvements 32:20, 33:3, 33:9 inc 1:6, 1:10, 125:11 inches 62:19 include 20:11, 44:3, 81:4 including 50:4, 56:17, 107:8	inclusive 17:4, 17:5, 17:7 incorrect 114:5 increased 106:17, 106:20 incredible 55:11 incubation 87:13, 87:19, 88:1, 88:7, 88:11, 88:13, 88:16, 119:17, 120:3, 120:11, 120:19 indicated 19:11 indicating 61:20, 89:13, 89:19 indications 114:16, 115:10 industries 1:10, 125:11 influence 12:9 information 5:8, 12:21, 15:19, 23:2, 63:21, 100:15, 103:20, 104:2, 104:6, 104:11, 104:12, 112:15, 113:10 initial 94:14 injection 29:16 inner 91:4 insert 114:13 insight 54:18 instance 2:5, 28:20 instead 9:21	instruct 25:8, 68:12 instructed 83:8 instructional 81:18 instructions 9:6 instructs 10:17 intended 81:4, 109:13, 114:20 intense 36:8, 38:16 intensify 36:9 intensity 71:20, 72:11 inter 8:21, 68:7, 68:10 interest 24:10, 24:11 interested 108:8, 109:8, 109:20, 125:22 interesting 89:12, 89:17 interior 74:15, 77:21 internal 54:22 international 3:4 interrupt 71:9 interruptions 6:19 invalid 69:1 invalidates 69:14 inventor 54:1 investigate 115:22, 116:5 investment 109:17
---	---	---	--

involve 100:20	86:16, 125:16, 126:5	37:16, 37:19, 38:8, 39:12, 40:3, 44:7, 44:8, 45:2, 45:16, 48:21, 49:5, 49:16, 49:17, 50:13, 50:17, 52:18, 53:2, 55:8, 55:11, 55:13, 55:15, 55:17, 55:21, 56:3, 58:19, 58:22, 60:1, 60:17, 61:1, 61:6, 61:8, 62:14, 63:9, 66:22, 69:9, 72:10, 72:13, 72:15, 72:19, 72:22, 76:21, 83:16, 84:7, 84:10, 84:20, 84:21, 86:9, 86:10, 86:11, 86:14, 88:5, 88:10, 88:12, 90:9, 90:13, 91:2, 92:1, 92:19, 93:2, 94:20, 95:16, 95:21, 99:17, 99:22, 100:1, 101:10, 102:13, 105:17, 108:18, 109:12, 110:1, 110:2, 110:4, 110:6, 111:10, 111:12, 112:8, 114:5, 120:4, 120:6	label 26:12
involved 101:19	K		labels 99:1
involvement 24:1, 24:6, 26:17	keck 29:3		lacks 39:5, 42:2, 70:5, 70:11, 79:15, 82:17, 106:12, 111:8
ip 37:8	keeping 56:4		language 48:20, 77:6
ipl 36:8, 37:8, 38:13, 38:14, 39:2, 39:18, 40:2, 40:8, 40:12, 40:22, 41:10	kelly 2:8, 7:15, 125:1, 126:12		large 55:4, 104:22, 105:4
ipr 1:13, 8:22, 23:13, 24:1, 24:16	kerastick 5:15, 62:3, 62:6, 85:18, 92:17, 100:20, 113:10, 114:14, 114:20		larger 62:19, 94:17
issue 23:12	kerasticks 91:12, 92:9		largest 43:5
items 15:2, 15:4, 33:21	keratoses 35:5, 35:7, 37:4, 50:3, 50:6, 53:2, 53:12, 57:11, 58:13, 59:15		larivees 120:13
itself 98:9	keratosis 49:21, 50:11, 51:1, 51:4, 51:21, 58:10, 59:11, 62:4, 105:20, 107:18, 108:3, 110:17, 111:4, 112:2		laser 29:8, 29:9, 29:17, 29:18, 29:19, 36:9, 36:10, 37:21, 37:22, 38:4, 38:13, 38:15, 38:18, 39:2, 39:18, 40:9, 40:12, 41:11, 41:13, 41:15, 41:17, 42:1, 42:4, 42:21, 42:22, 43:18, 44:8, 44:9, 44:14, 44:16, 45:1, 48:8, 53:7
J			lasers 15:22, 45:8, 51:8, 53:4, 53:5
james 3:10, 7:4, 96:11	killed 88:9		last 16:15, 17:1, 27:8, 27:9, 34:13, 50:21, 53:3, 106:13, 106:18, 121:8, 122:11, 122:19
january 61:7	kind 15:8, 49:16, 61:2, 110:8		late 51:16, 61:2
job 56:9	kinds 117:13		
johnson 95:5	know 16:8, 18:6, 20:1, 25:20, 35:19, 36:21, 37:1, 37:8, 37:9, 37:12,		
joules 40:2			
journal 116:8			
joy 12:3			
jpmurphy@polsine- lli 3:16			
july 1:22, 2:7,			
		L	
		l-shaped 84:7	

later 10:15, 13:4, 39:15, 54:22 law 18:8 laymen 48:21 layperson 74:5 leading 119:9, 119:19, 120:7, 120:13, 120:21 leeway 116:16 left 48:10, 50:5, 68:2, 75:2, 75:15, 75:20, 76:8, 76:15, 77:2, 78:21, 82:1 left-hand 77:11, 79:8, 79:18 leg 29:16 legal 27:13 length 76:18, 76:19, 77:18 lesions 53:16, 100:21 less 14:13, 16:12, 17:4, 17:12, 43:3, 51:17, 95:19 let's 20:18, 42:18, 43:2, 43:17, 72:20, 77:6 letter 74:11 letting 105:17 level 44:13	levu 67:5 levulan 5:15, 37:15, 37:20, 50:12, 50:13, 50:15, 56:22, 60:5, 60:9, 62:2, 62:6, 67:6, 85:18, 87:20, 88:1, 92:16, 100:20, 107:9, 111:19, 112:4, 112:14, 113:10, 114:14, 114:19, 118:16, 119:2, 119:4, 119:13, 119:18 liberty 13:9 life 49:3 lifetime 106:10 lift 58:22 light 15:22, 35:3, 35:8, 36:8, 36:17, 36:18, 36:22, 37:19, 38:6, 38:7, 38:16, 38:17, 38:19, 56:22, 59:5, 60:6, 60:12, 60:18, 62:19, 63:1, 63:5, 70:19, 71:20, 72:9, 72:11, 73:17, 73:18, 91:18, 92:3, 95:2, 115:14 light-based 56:16 light-emitting 82:14 lighting 97:16, 97:21	limit 43:8 limited 23:20 line 78:12, 78:13, 79:8, 79:18, 117:22, 124:2 linear 78:8, 78:20, 79:3, 79:7, 79:11, 79:17, 79:20 liner 82:22 lines 32:10, 33:18, 34:1, 35:16 liposuction 29:15 list 4:4, 21:6, 45:9, 64:14, 81:4 listed 14:10, 27:12, 27:14, 27:21, 28:17, 33:16, 44:3, 64:13 listen 56:6 listing 33:8 literature 93:1, 119:1 litigation 24:3, 24:8, 24:12, 24:16 little 35:10, 71:16, 90:7 llp 3:20, 3:28, 3:36, 17:21 located 2:9, 7:16, 7:17 long 14:12, 30:11,	46:1, 86:20, 121:1 longer 41:7, 53:6, 76:14, 79:10, 79:20 look 11:15, 16:5, 31:15, 57:17, 61:19, 62:15, 74:14, 93:9, 116:9 looked 90:16 looking 33:14, 45:8, 69:15, 71:3, 73:22, 102:2, 104:5, 109:11, 110:5, 115:21, 117:12 looks 19:13, 38:5, 101:14, 111:12, 114:13 los 30:6 lost 89:2 lot 34:21, 116:15 louisiana 3:12 love 56:1 low 40:3, 95:9, 95:10 low-lit 37:19 lumecca 36:8 lumps 29:13 lundahl 65:12, 69:19 lying 92:5
--	--	---	---

M			
ma	101:19, 101:20	92:12, 99:20,	methods
3:6	manufacturers	101:7, 106:13,	51:3
ma'am	44:9	109:5, 110:3,	meticulous
19:1, 21:15	many	111:9, 112:1,	58:19
machine	16:13, 49:18,	115:3, 117:12	mic
58:20, 80:4,	52:12, 56:8,	means	6:10
80:16, 94:4,	60:10, 60:13,	60:9	michael
94:6, 99:21	111:4	meant	16:2, 16:9
maddie	marked	100:9	microder
3:37	18:17, 27:3,	measure	29:17
made	31:6, 65:5,	63:13, 82:13,	micrographic
24:22, 38:1,	81:19, 85:13,	83:6, 84:16	28:20
99:21	85:15, 98:15,	media	microscopic
mainly	98:17, 103:6,	17:18	50:5
13:18	112:18	medical	middle
maintained	market	13:18, 29:7,	82:21, 84:14,
58:15	44:9, 50:3,	30:9, 30:13,	84:20
maintenance	51:1, 104:16	34:7, 34:8,	might
58:18	marks	34:11, 35:6,	49:14, 74:5,
majority	4:11	50:4, 55:18,	95:5, 97:12,
58:12	marriage	55:19	117:20
make	125:20	medication	migraines
20:5, 44:19,	maryland	115:17	95:1
45:10, 50:12,	126:18	medications	millimeter
50:15, 50:18,	mask	50:8, 54:19	43:3
81:14, 82:19,	38:10	medicine	millimeters
90:20, 91:1,	materials	29:4, 44:21,	43:10, 43:12,
92:1	64:12, 64:14,	54:22, 110:3	43:14
makes	116:9	meet	mind
26:14, 93:1,	matter	14:12, 16:14	30:1, 108:15
115:15	24:3, 24:7,	meeting	mine
makeup	109:15, 126:1	16:15, 17:1	66:3, 88:6
54:19	maybe	meetings	minor
making	37:7, 39:15,	14:15	20:7
10:13, 53:16,	60:3, 61:3, 66:2	melanoma	minute
83:16, 117:8	mayo	37:5	72:7, 88:16,
malignancies	83:22, 84:6	mental	95:17, 96:2,
29:13	md	12:8	117:21
malpractice	30:9, 30:12	mention	minutes
13:18	mean	20:13, 115:13	37:19, 37:20,
manifestations	39:20, 40:5,	mentioned	38:7, 46:2,
55:2	45:15, 45:17,	13:22, 16:11,	46:4, 46:7,
manipulate	49:1, 55:7,	17:3, 52:5, 81:3	46:8, 46:9,
50:18	57:8, 58:18,	met	63:7, 91:18,
manual	59:1, 60:16,	14:9, 16:11	117:20
90:12, 90:16,	63:3, 65:22,	metal	misremembered
	70:12, 78:10,	83:22, 84:1	122:22
	81:12, 89:5,	method	missed
		94:10	102:4

missing 97:19 misspoke 113:7 modalities 52:13 modality 32:16, 51:19, 53:10 modify 44:10 modulators 51:7 mohs 28:20 moment 30:2, 31:14, 65:13, 88:20, 92:8, 93:7, 102:19, 103:13, 112:12, 112:16, 121:5 monday 122:3 money 110:2 month 60:14 months 20:2, 60:20, 111:3 more 9:7, 33:7, 34:14, 35:3, 44:15, 45:11, 49:16, 53:16, 60:10, 71:10, 88:2, 88:14, 95:18, 97:13, 108:9, 108:10, 110:2, 110:6, 116:1 morning 7:10, 8:8, 11:21, 17:11 most 29:20, 40:5, 42:4, 51:5,	51:15, 51:20, 94:16 mouse 19:2, 89:8, 89:17 move 19:2, 91:2, 94:4, 94:5, 100:7 moving 58:20, 83:1, 89:17 much 5:18, 50:9, 50:10, 51:13, 51:14, 59:7, 59:17, 83:3, 89:20, 90:1 multiple 42:5, 44:11, 52:12 murphy 3:10, 7:5 mute 6:9 mydrugrep 99:7, 99:10 myself 14:16, 38:2, 110:22 N name 12:2, 12:3 names 12:5 nanometers 41:18 natural 41:4 necessarily 4:12, 34:19 neck 21:19, 85:3, 91:5, 91:9, 91:10, 91:13, 91:20, 92:6, 92:9, 92:14	necks 21:3, 21:20, 80:22 need 10:6, 49:6, 74:11, 84:21, 110:6, 122:12 needed 49:10, 49:14 needs 43:20 neglected 20:11 nerve 88:3 never 50:7, 55:9, 57:6, 66:13, 87:22 new 3:31, 34:15, 107:4, 109:18 next 10:2, 28:22, 81:17, 87:21, 97:12, 104:20 nod 36:4, 47:12, 61:18, 87:9, 93:8, 100:16 non-melanoma 37:5 non-mohs 29:12 non-precancerous 37:7 none 53:7 nose 48:11, 82:22 notary 124:28, 125:2 note 4:11 noted 16:7, 64:2, 124:15 nothing 8:4, 85:6	notice 71:20 november 18:1, 18:4, 18:7, 61:3, 61:6, 86:2 number 5:5, 7:18, 9:1, 21:17, 21:18, 33:15, 37:2, 49:9, 49:14, 49:22, 65:12, 67:21, 95:9, 95:10, 112:22 numbered 2:6, 8:21 numerous 35:4, 37:4, 70:13 nurse 44:21 nursing 55:20 ny 3:31 O oath 8:5, 9:10 obesity 95:4 object 71:1, 115:1, 115:4 objecting 115:7 objection 10:17, 39:4, 41:1, 42:2, 42:14, 44:5, 45:13, 47:17, 47:21, 50:1, 57:5, 59:13, 59:20, 62:12, 63:12, 68:18, 70:4, 70:10, 70:22, 72:1, 72:6, 73:3,
--	---	---	---

74:8, 74:13, 75:10, 76:16, 77:16, 78:1, 78:9, 78:17, 79:2, 79:14, 80:1, 80:10, 80:14, 82:3, 82:16, 86:8, 90:14, 95:7, 99:11, 99:19, 100:6, 101:5, 101:12, 106:11, 107:6, 108:16, 109:6, 110:10, 110:20, 111:7, 111:21, 112:6, 113:11, 115:19, 116:6, 116:13, 117:3, 117:10, 117:17, 119:8, 119:19, 120:7, 120:13, 120:21 objections 10:14, 11:2, 117:1 obtain 104:10 obtained 21:1, 63:11, 104:12 obviously 96:9 occasions 16:13 occurred 125:14 october 18:10, 18:11 off-the-record 6:8 offer 71:10 offered 15:1, 45:9, 94:17 offers 32:14 office 1:1, 9:2,	10:14, 35:21, 42:21, 55:21, 59:11, 59:18, 70:18, 70:20, 83:7, 88:9 often 37:16, 48:21, 51:20, 59:17, 60:1 oh 27:18, 46:5, 84:1, 97:19, 107:20, 113:21 older 108:11 once 12:15, 23:1, 48:22, 57:8, 61:5, 64:20 one 3:4, 6:6, 14:1, 20:7, 20:19, 21:16, 29:5, 32:16, 38:6, 38:18, 41:17, 45:9, 45:11, 48:10, 48:12, 49:2, 49:15, 49:20, 50:14, 52:8, 53:15, 54:21, 54:22, 61:3, 66:19, 69:20, 71:5, 72:13, 72:22, 76:20, 78:12, 86:14, 87:20, 88:5, 90:7, 91:3, 91:12, 91:13, 91:17, 91:20, 92:9, 93:3, 93:13, 93:21, 94:13, 95:8, 102:19, 103:19, 111:3, 112:11, 120:4, 121:5 one-and-done 50:8	one-dimensional 78:10, 78:20 ones 44:3 ongoing 50:7 only 14:1, 27:20, 49:2, 68:12, 85:2, 88:5, 117:13 open 25:2 operating 30:12, 101:18, 101:20 opinion 13:2, 108:7, 109:8, 109:20 opinions 15:1, 23:16, 64:5, 64:19 opportunity 11:3, 11:17 opposed 120:6 option 32:15 options 60:7 oral 1:20, 2:3 oranges 80:2 order 42:19, 121:18, 122:4 ordering 121:22 orientation 71:8, 71:13, 71:16, 77:22 orientations 77:4, 77:5, 77:8 other 9:21, 10:7, 12:5, 13:14,	16:6, 17:14, 21:16, 22:19, 23:4, 23:22, 24:5, 24:11, 28:16, 34:6, 35:20, 40:11, 40:12, 41:10, 45:10, 49:13, 49:20, 52:5, 53:10, 58:10, 58:17, 62:20, 63:2, 63:19, 64:2, 64:3, 68:14, 71:5, 72:14, 73:2, 75:13, 76:20, 84:15, 91:3, 107:12, 116:2, 119:16 others 44:11 otherwise 125:22 out 53:8, 83:5, 88:20, 89:3, 89:5, 89:10, 93:19, 95:8, 102:16 outcome 23:12, 126:1 output 39:18, 40:21, 63:10, 63:14 outside 45:14, 61:4, 90:15, 112:7, 115:1, 115:8, 116:6, 116:13, 116:19 over 6:6, 9:20, 10:21, 53:16, 55:9, 57:22, 58:2, 58:14, 71:18, 82:18, 89:15, 95:13, 96:12, 106:4,
--	---	--	--

106:9, 106:13, 106:17, 106:21, 107:10, 108:11, 118:20 overall 32:19, 35:8 overbroad 44:6, 68:18, 110:21, 115:20, 116:7, 117:10 overhead 106:14, 106:17, 107:1, 107:13 overleaning 76:19 own 24:19, 30:6, 55:17, 59:1, 105:6, 119:2 owned 59:4 owner 1:11, 3:18, 7:9, 8:17	paper 11:20, 15:19, 97:13 papers 63:17 paragraph 20:12, 20:17, 20:21, 22:8, 23:11, 32:4, 32:8, 33:2, 36:1, 36:4, 47:8, 47:12, 48:15, 54:6, 56:12, 56:15, 57:12, 57:17, 61:17, 61:19, 62:16, 63:20, 70:15, 73:7, 73:9, 73:12, 80:20, 87:3, 93:6, 93:10, 97:10, 99:4, 100:14, 100:16, 103:19, 104:21, 114:17, 115:11 parallel 74:17, 74:20, 75:7, 75:8, 75:12, 75:16 parameters 40:12, 40:15, 41:10, 42:5, 44:11 pardon 85:22 park 3:29 part 15:21, 23:15, 39:9, 56:2, 81:15 partes 8:21, 68:7, 68:10 particular 40:21, 41:19, 49:15, 50:14 parties 13:6, 13:8,	125:19, 125:21 party 120:6, 125:10 pass 61:6, 117:21, 118:9 past 15:7, 37:8, 49:8, 118:1 patent 1:1, 1:4, 1:11, 1:14, 3:18, 5:4, 7:9, 8:17, 8:22, 9:2, 10:14, 13:20, 16:5, 24:2, 24:11, 65:11, 65:17, 66:11, 66:12, 66:13, 67:10, 67:12, 69:1, 69:15, 69:19 patents 54:1 patience 103:1 patient 37:17, 37:18, 41:3, 41:8, 43:20, 53:11, 56:1, 57:10, 59:12, 61:3, 81:8, 82:19, 82:21, 83:9, 84:4, 88:3, 91:1, 92:4, 94:1, 94:4, 94:5, 94:11, 94:13, 95:8, 111:2, 111:11 patient's 33:3, 48:11, 65:18, 70:6, 75:3, 75:8, 75:9, 75:16, 76:5, 76:9, 77:12, 78:21, 79:9, 79:19, 82:1, 82:13,	82:14, 85:3, 90:21, 92:2, 93:12, 95:3 patients 21:3, 33:9, 34:21, 36:20, 37:2, 40:5, 44:1, 45:4, 52:12, 52:20, 55:5, 55:17, 56:1, 58:21, 60:10, 60:15, 60:17, 80:22, 87:20, 93:13, 94:16, 100:9, 106:5 payments 25:1, 25:2 pc 3:11 pd 51:20 pdt 32:14, 36:2, 36:7, 36:13, 39:2, 47:9, 47:16, 47:20, 49:6, 49:22, 53:9, 59:10, 59:17, 59:22, 61:14, 62:20, 63:2, 104:21, 105:20, 106:2, 106:9, 108:9 peel 53:2 peels 29:16, 51:7, 52:17 pending 10:8 penetrate 50:16 penetrating 50:12 penetration 42:16, 50:19 people 61:8, 61:14,
P			
pacific 96:8 packing 29:14 page 4:2, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 4:9, 5:3, 5:17, 20:21, 21:17, 28:2, 31:12, 36:1, 47:9, 66:2, 79:13, 79:22, 81:17, 85:21, 86:1, 88:21, 90:4, 97:10, 97:12, 99:6, 100:11, 101:15, 101:17, 104:14, 124:2 pairing 112:9			

110:5, 119:16 percent 48:9, 51:17, 52:4, 52:14, 62:7, 62:10 percentage 51:9, 52:2, 52:9, 52:10, 52:16, 53:4, 62:14, 111:13 perfect 89:22 perfectly 116:22 performed 36:7, 36:13 performing 39:12 perhaps 102:6 periodically 10:5, 17:2 person 39:1, 39:11, 39:15, 88:5 personal 105:6 personally 110:18 perspective 55:1 pertaining 8:22, 15:9, 15:12 petitioner 1:8, 2:5, 3:2 petitioners 7:4 pharma 1:7, 7:9, 8:17, 24:2, 24:20, 24:22, 92:21 pharma's 10:13, 57:14, 62:1, 62:17 pharmaceutical 1:10, 125:11 pharmaceuticals 24:13, 25:6,	31:9, 66:22, 67:3, 67:7, 68:3 phone 6:14, 14:18 photo 31:8, 70:17, 75:21 photodynamic 5:17, 15:21, 26:15, 31:13, 33:10, 36:15, 51:8, 51:11, 51:16, 52:21, 56:17, 56:19, 56:20, 57:3, 57:6, 57:9, 60:8, 61:4, 61:9, 62:3, 63:17, 73:18, 91:6, 106:20, 107:4, 107:17, 108:3, 110:16, 114:21, 115:14, 115:16 photolight 114:21 photos 73:16, 104:5 photosensitizer 36:17, 56:21, 116:1, 116:5, 116:11, 117:7 photosensitizers 116:2 phrase 110:7 physical 12:8 physician's 55:19 physics 44:14, 45:1 picture 71:3, 71:11, 73:8, 74:1, 74:14, 75:2, 75:4, 75:14, 76:8, 76:14,	76:15, 77:2, 77:11, 77:20, 78:7, 79:9, 79:12, 79:18, 79:22, 82:6, 82:9, 82:10, 98:22, 99:20 pictures 81:18 pigment 41:5, 41:6 place 3:4, 20:7, 96:12, 110:4 plain 60:11, 60:18 planet 126:14 plastic 82:22, 91:4 please 6:5, 6:6, 6:9, 6:11, 6:14, 7:1, 7:20, 10:8, 12:1, 18:12, 18:13, 22:2, 23:5, 26:21, 28:10, 31:4, 31:14, 31:21, 47:5, 47:11, 47:18, 56:13, 56:18, 65:2, 66:14, 67:9, 67:21, 72:3, 85:11, 97:5, 98:13, 100:15, 101:22, 103:8, 103:14, 112:14, 112:22, 114:7, 114:11, 115:5 plus 59:3 point 11:2, 93:3, 93:19 pointing 61:22 polsinelli 3:11, 8:9,	121:21 popular 52:19 portion 74:19, 79:12, 79:21, 85:1, 87:2, 87:12, 100:11, 114:12 portions 74:17, 74:20, 75:7, 75:12, 75:16 position 81:7, 81:12, 82:18, 83:9, 83:10, 83:12, 83:21, 91:15, 94:7 positioned 84:14 positioning 73:17, 82:12, 85:2, 97:22 possibility 97:2 possible 101:3 posted 17:17 power 39:17 practice 23:9, 26:9, 30:6, 30:8, 30:16, 31:1, 39:19, 51:10, 51:12, 52:2, 53:7, 57:15, 57:19, 87:19, 105:5, 105:9, 105:12, 107:2, 107:14, 108:8, 109:8, 109:20, 111:1 practices 105:1 practicing 34:22, 52:19
---	---	--	---

practitioners 44:21, 51:14 pre 49:7 precancerous 32:11, 33:19, 34:10, 35:14 preceding 49:7 prefer 28:7 preparation 14:22, 16:12, 37:12, 64:12 prepare 10:22, 11:4, 14:4 preparing 64:16 prescribing 5:7, 112:14, 113:10 present 3:35, 14:14, 14:18, 23:13, 24:12, 24:15 presented 35:19 presenting 11:9 presently 9:1, 30:5 prestigious 55:4 pretty 83:3 prevent 12:10 price 60:10, 104:16, 107:5, 107:9, 107:11, 107:17, 108:2 prices 106:13, 106:20 pricing 104:6, 104:10, 104:12	primary 30:18 printout 31:10 prior 69:2, 69:14, 69:20 private 30:6 pro 86:2 probably 27:9, 51:5, 51:15, 51:17, 52:4, 53:2, 95:19 problem 35:7, 53:11, 102:13, 111:15 procedure 2:11, 39:13, 47:15, 47:19, 48:4, 48:15, 48:18, 50:18 procedures 29:8, 29:9, 29:19 proceed 8:1 proceeding 6:3, 6:7, 116:18 proceedings 123:4 process 47:10 produced 2:4 products 54:20 professionally 12:5, 16:9 professor 29:3, 88:6, 88:14 promotional 116:9 proper 90:11	properly 83:9 provide 6:16, 98:1, 100:4 provided 20:3, 64:3, 64:17, 105:16 ptab 2:11 public 124:28, 125:2 publications 27:11 published 18:14, 63:16 pull 93:7 pulling 86:22 pulse 40:16, 42:6, 44:4 pulsed 29:18, 36:8, 38:16, 41:15 purchase 6:18, 108:9, 115:16, 117:9 purchased 57:18, 58:7, 108:5 purchasing 105:6, 109:21 purposes 6:7 put 11:12, 18:19, 26:21, 28:4, 36:19, 38:5, 38:9, 56:8, 69:13, 84:8, 89:18, 102:13, 103:3 Q qualifies 54:15, 56:9	question 9:22, 10:2, 10:8, 10:9, 15:16, 16:21, 23:6, 24:15, 25:8, 36:5, 39:8, 39:10, 39:16, 45:16, 47:2, 47:7, 47:13, 47:18, 48:3, 49:19, 49:20, 51:2, 62:13, 64:8, 64:21, 65:10, 65:13, 65:14, 66:7, 68:13, 68:21, 69:4, 72:3, 72:19, 72:21, 76:12, 76:22, 78:18, 79:6, 79:16, 103:9, 107:16, 108:1, 109:4, 114:7, 114:11, 114:16, 114:19, 115:7, 117:5, 119:11, 119:22, 120:15 questions 9:9, 9:10, 10:16, 11:1, 11:17, 12:10, 19:9, 19:22, 31:16, 61:17, 118:11, 121:4, 121:12 quick 45:21, 121:17 quotation 4:11 quote 4:13, 100:19, 104:15 quoted 60:10 quotes 48:5, 48:19 quoting 63:3
---	---	---	--

R			
radiant	47:22, 48:5,	referenced	120:11
34:15	110:1, 110:8,	50:22	relation
raise	110:9, 110:14,	references	23:13
7:19, 107:4	124:2	69:20	relative
rare	reasons	referencing	83:12
52:20, 91:8	49:18, 53:13,	21:18, 48:14,	relied
rarely	110:8	48:16, 73:13	64:4
59:22	recall	referring	remember
rash	13:5, 17:20,	24:16, 63:2,	6:5, 6:9, 86:17
13:3	18:5, 18:11,	63:5, 67:12	remote
rashes	26:1, 26:4,	refers	3:37, 6:2,
111:10	59:7, 65:16,	36:15	11:7, 18:15,
ratchet	65:20, 99:16,	reflect	18:22, 22:3,
37:9	118:14, 118:17,	4:12	27:1, 27:16,
rate	120:9, 120:17	reflected	31:5, 31:22,
22:10, 22:16,	receive	35:4	56:5, 65:4,
22:17, 22:18,	23:19, 122:3	reflection	65:6, 66:16,
23:8	received	35:9	89:4, 89:11,
raymond	118:15, 119:16,	refresh	89:16, 89:21,
3:27, 7:8	120:11, 120:19	14:22	97:8, 102:1,
re-click	receiving	refreshed	102:7, 102:12,
89:6	118:19	15:2	102:17, 102:20,
reaction	recognize	regarding	103:2, 103:15,
57:1, 57:8,	98:19	15:19, 63:17,	112:17, 113:17,
111:1	recollection	103:21, 120:2	113:21, 114:3,
read	14:22	regimen	122:9, 122:14,
36:3, 47:11,	record	38:9	122:21
87:1, 87:10,	6:22, 7:2,	region	remotely
100:15, 100:17,	12:2, 46:14,	92:13	1:23, 6:4
114:6, 114:11,	46:18, 96:14,	registration	removal
114:12, 116:8,	96:19, 105:15,	126:15	29:13, 29:17
117:5, 124:13	117:20, 118:2,	regular	remove
ready	118:7, 122:7,	29:18, 56:6	37:20
36:4, 47:12,	123:2, 125:9	reif	repair
117:20	recorded	3:37, 18:13,	10:22
reality	56:5	21:13, 22:1,	repeat
49:5	recording	26:20, 97:7,	47:18, 78:18,
really	6:7, 6:17	101:21, 103:13,	79:16, 120:15
39:7, 44:12,	records	112:13	rephrase
48:7, 57:6,	67:18	reimbursements	119:10
58:17, 60:16,	red	107:10	replaced
61:10, 71:5,	38:4, 41:21,	rejuvenation	59:5
117:18, 121:17	62:19, 63:1,	47:9	report
realtime	63:5	related	24:22, 64:6,
114:9	redirect	119:17, 120:18,	73:8, 80:20,
reason	4:7, 97:3,	125:18	85:1, 97:11,
10:7, 12:7,	121:6, 121:9	relating	99:4
	refer	24:12, 120:3,	reported
	39:20, 53:8		1:23, 25:1

reporter 6:12, 6:21, 7:12, 7:14, 7:16, 7:22, 9:18, 10:22, 11:12, 42:9, 46:13, 46:17, 96:14, 96:18, 114:11, 118:2, 118:6, 121:14, 121:17, 122:2, 122:7, 123:2, 125:1 reporter's 4:9, 4:11 reports 64:14 represent 19:5 representation 78:20 represented 8:11, 125:12 representing 7:9, 8:10, 8:14, 8:17 requested 114:12 require 5:19 required 10:15, 49:22 research 119:1 researching 45:17 residencies 54:21 residents 29:7 respect 41:13 rest 110:4 restroom 10:7 results 21:2, 36:9,	63:15, 72:15, 72:18 resurfacing 29:19, 51:7, 53:6 retained 5:2, 18:3 return 109:17 reveal 12:21, 14:7, 15:16, 23:2, 25:8, 64:8, 64:21, 69:4 revenue 105:9, 105:11, 106:8, 106:16 reverse 42:18 review 8:21, 11:3, 64:11, 66:1, 68:7, 68:10 reviewed 14:9, 14:21, 15:13, 15:18, 16:2, 66:10, 108:18, 110:12, 119:1 rhabbaz@desmarai- sllp 3:33 rhodo 26:15 rhodoled 25:13, 103:21, 104:16, 104:22, 110:13 right 7:19, 9:16, 11:10, 19:4, 19:20, 20:12, 22:5, 23:13, 27:5, 32:12, 33:16, 34:1, 34:3, 34:11, 34:18, 49:1, 57:19, 61:15,	61:18, 62:4, 62:7, 69:15, 71:12, 73:14, 74:2, 77:3, 77:8, 77:22, 78:5, 78:8, 78:22, 80:5, 80:13, 85:4, 85:7, 85:9, 86:3, 87:14, 92:11, 93:15, 95:6, 98:9, 98:18, 102:21, 103:12, 104:7, 106:22, 108:21, 109:14, 110:3, 118:20, 119:2 right-hand 82:9 rising 107:1, 107:13 risk 100:14 roberts 1:21, 2:4, 5:10, 5:13, 5:22, 8:2, 8:8, 8:19, 12:3, 12:4, 12:7, 12:13, 15:11, 17:20, 18:18, 19:5, 19:17, 21:9, 22:7, 25:4, 25:12, 27:4, 27:22, 28:15, 30:3, 30:9, 30:11, 30:12, 31:7, 32:3, 46:19, 47:6, 50:20, 53:22, 54:5, 54:8, 56:14, 58:5, 61:16, 61:22, 63:6, 63:19, 65:9, 65:14, 66:21, 68:1, 68:5, 68:20, 69:22,	70:14, 70:19, 71:19, 72:20, 73:6, 73:22, 74:10, 75:1, 75:20, 77:1, 79:6, 80:19, 85:14, 86:22, 88:21, 90:3, 93:8, 96:20, 97:6, 97:9, 98:16, 100:13, 103:7, 103:18, 108:7, 108:21, 112:19, 113:8, 118:9, 118:10, 121:8, 124:19, 124:24, 125:4, 125:14 rock 95:5 rockville 126:18 role 23:22, 24:5, 29:2 room 11:21, 72:10 rotated 80:4, 98:1 rough 122:4 roughly 74:6, 75:8 rpr 2:8 ruler 83:5, 84:15 rules 2:11, 116:18 run 6:4 running 107:14 rush 122:1 S safer 41:8
--	--	--	---

said 9:19, 51:12, 92:8, 113:2, 124:23 sallow 35:3 same 9:15, 21:18, 47:15, 47:20, 47:21, 59:20, 63:7, 63:10, 63:15, 74:13, 76:18, 80:13, 83:12, 94:6, 99:3, 101:9, 106:2, 109:6, 117:17, 121:21, 121:22, 122:11, 124:15 same-looking 66:9 san 2:10, 3:23, 7:17, 125:15 say 13:9, 24:15, 35:12, 42:10, 43:2, 43:17, 44:2, 45:7, 47:2, 48:7, 48:18, 48:22, 51:15, 52:4, 52:13, 60:2, 60:14, 68:15, 70:12, 106:7, 108:19, 111:16, 113:3, 113:4, 121:2 saying 39:11, 106:19 says 21:19, 32:14, 32:19, 34:14, 49:8, 57:18, 73:17, 86:2, 87:3, 87:12, 104:15 scalp 20:12, 20:14,	21:6, 21:21, 82:7, 83:13, 83:14, 83:18, 85:3, 87:15, 100:21, 101:4, 101:8, 101:9 scalps 81:4 schedule 60:19, 60:20 school 29:4, 55:19, 55:20, 60:19 sclerotherapy 29:15 scope 45:14, 90:15, 112:7, 115:1, 115:8, 116:7, 116:14, 116:19, 116:22, 117:11 screaming 88:9 screen 11:9, 18:20, 19:1, 27:5, 61:18, 68:3, 89:6, 89:13, 97:7, 98:14, 98:18, 103:5, 112:15 screening 94:20 screenshot 86:6 screenshots 84:22 scroll 11:14, 18:20, 19:7, 27:15, 67:19, 67:20, 101:16, 103:8, 112:21, 113:15 scrub 37:14 seasonality 61:11 seated 93:16	sec 20:19 second 33:15, 47:16, 47:20, 66:19, 66:20, 73:13, 103:20 seconds 91:18 section 28:22, 30:3, 34:13, 63:22, 83:18 sections 99:2 see 11:14, 20:18, 22:12, 27:20, 30:4, 32:8, 32:17, 32:21, 33:9, 34:16, 35:1, 35:8, 35:15, 36:11, 49:11, 54:8, 55:5, 55:14, 56:12, 57:8, 62:21, 63:22, 67:20, 68:2, 68:18, 71:5, 71:7, 71:9, 72:11, 72:20, 73:10, 73:12, 73:20, 74:1, 74:14, 75:2, 75:4, 75:16, 76:6, 76:8, 76:10, 76:21, 77:11, 77:14, 77:20, 78:5, 81:10, 81:20, 81:22, 82:6, 82:9, 84:18, 84:22, 86:4, 86:5, 87:5, 87:16, 89:6, 89:7, 96:13, 99:8, 99:18, 101:1, 102:3,	103:22, 104:18, 104:19, 105:1, 105:2, 108:12, 111:2, 111:14, 112:22 seeing 27:5, 45:4, 55:8, 55:17, 65:16, 65:20, 75:21, 76:3, 77:1, 77:2, 77:7, 77:22, 78:3, 78:7, 78:19, 79:3, 82:1, 82:4, 102:3, 111:1, 111:3 seeks 71:1 seen 55:10, 65:15, 66:5, 66:12, 66:13, 113:13 seizures 95:1 select 40:21 sense 52:1, 70:2, 70:9, 93:1, 105:8 sentence 21:1, 33:15, 34:13, 49:7, 49:16, 108:15, 109:13, 109:19 series 15:22, 60:1, 90:6 served 13:13, 13:16, 13:19 services 22:11 serving 13:10, 17:21, 25:14, 25:17, 25:21
--	---	--	---

session 91:17 set 2:12, 53:15, 71:14, 125:5, 126:4 setting 40:2 settings 41:22, 43:22, 44:2 seven 71:21 severe 35:1 shape 74:1, 74:6, 74:11, 76:5 share 105:13 sheath 88:3 sheet 88:8 shorter 79:10, 79:20 shorthand 7:16 should 6:8, 9:21, 41:12, 100:20, 102:22 shoulder 78:21, 78:22, 79:9, 79:19, 93:19, 94:8 shoulders 77:12, 93:20 show 88:21, 100:10 showing 57:13, 61:18, 69:22, 80:20, 85:2, 85:6, 85:15, 85:17, 98:17, 113:9 shown 31:8, 65:10,	70:3, 70:15, 79:12, 79:22, 85:1, 90:5, 97:11, 100:4 shows 70:6 sic 34:14, 107:19 side 35:15, 68:2, 83:2, 91:3, 93:21 sides 75:8 signature 4:8, 124:1, 124:14 signature-plkal 126:10 significant 27:11, 56:3, 106:8, 108:10, 108:14, 109:1, 109:5, 110:1, 110:8, 110:9, 110:14 signs 32:6 similarly 71:12 simple 107:16, 107:22 simply 81:7 simultaneously 100:22, 101:4 since 20:2, 30:19, 51:15, 55:9, 55:13, 59:22, 63:8, 88:10, 106:2 single 35:2, 50:5 sir 122:15 sitting 20:1, 84:5,	94:2 situation 109:9 six 88:2 size 42:5, 42:13, 42:15, 42:17, 42:19, 42:22, 43:5, 43:6, 43:18, 44:3, 95:3 skill 39:1, 39:12, 39:15, 54:13 skin 32:20, 33:3, 34:15, 35:3, 35:4, 35:9, 35:17, 36:20, 37:5, 37:14, 38:5, 38:10, 41:21, 43:1, 43:2, 43:7, 47:9, 49:18, 50:19, 54:20, 55:6, 57:1, 88:2 skull 76:5 slam 58:21 slowly 6:5 small 37:1, 87:1, 91:15 smaller 66:3 smallest 42:19 smoking 32:7, 49:8 smoothing 35:17 smoothly 6:4, 9:7 social 17:17	soft 28:10 some 9:6, 9:9, 15:2, 15:6, 37:6, 38:20, 38:22, 44:10, 44:22, 50:14, 53:10, 60:20, 93:3 somebody 99:22 someone 79:6, 91:8, 94:22 something 80:17, 101:14 sometimes 34:6, 50:10, 50:13, 60:22, 111:11, 111:12 somewhere 40:6 soon 103:3 sorry 7:12, 7:14, 20:19, 42:9, 71:9, 84:1, 97:18, 97:20, 107:15, 112:20, 122:9 sounds 11:19 source 36:17, 36:18, 36:22, 56:22 sources 70:19 southern 34:22, 51:13 spa 44:20 space 5:18 spaced 71:4 speak 6:5, 110:22,
--	--	--	--

116:8 speaking 6:12, 6:15 special 36:2 specific 63:4, 116:1, 116:5 specifically 63:13, 109:10, 112:9, 115:13 specifications 39:21 specify 36:18 spectrum 38:14, 38:20 speculate 74:11, 109:9, 115:2, 117:18 speculation 74:9, 99:12, 101:6, 101:13, 107:7, 108:17, 110:11, 110:21, 111:22, 112:7, 115:9 spellings 121:15 spend 56:3 spending 110:2 spent 32:6 spoken 17:14, 18:10 spot 42:5, 42:13, 42:15, 42:22, 43:5, 43:6, 43:9, 43:18, 44:3, 50:14 spots 32:11, 33:19, 34:8, 34:10, 35:14, 37:7, 41:6	spread 84:9 spring 38:10, 51:16, 61:2, 61:7 spurt 42:7 square 62:18 staff 58:19, 83:8, 107:13 stand 18:16, 27:1, 31:5, 58:22, 65:4, 83:22, 84:6, 84:9, 102:1, 112:17 standard 22:16, 22:17, 22:18, 23:8, 36:10 stands 117:4 stare 72:8 staring 72:10 start 9:22 started 9:5, 16:15, 17:1, 52:18, 118:19 starting 10:2, 54:16 state 2:9, 7:1, 12:1, 22:9, 23:11, 36:7, 62:16, 80:21, 81:6, 97:16, 97:21, 104:21, 108:7, 124:21, 124:29, 125:2, 125:15 stated 109:7 statement 11:4, 22:14,	22:15 states 1:1, 5:4, 9:2, 44:22, 56:15, 57:13, 62:17, 100:19 stating 109:19 step 87:3 stick 107:9 stipulations 4:3 stock 24:19 stool 94:3 stop 47:10 straight 74:17, 74:20, 75:7, 75:12 street 3:12, 3:21 stress 12:9 strike 31:10, 37:17, 75:19 students 29:7, 55:18 studied 26:12 studies 15:6, 15:8, 15:9 subject 24:3, 24:7 submitted 116:17 subscribed 124:23 subsequent 13:3, 20:12 substance 12:9, 23:16, 46:20, 96:22	sufficient 96:2 suite 3:5, 3:13, 3:22, 126:17 summer 60:20, 61:2 sun 1:10, 7:9, 8:17, 10:13, 24:2, 24:12, 24:20, 24:22, 25:5, 31:9, 32:7, 34:21, 35:1, 35:2, 36:21, 36:22, 49:8, 51:14, 57:13, 61:22, 62:17, 92:21, 93:3, 125:11 sunscreen 38:11 supplemental 5:21, 103:11 supplies 107:8 suppose 39:7 supposed 116:16 sure 39:7, 45:22, 46:3, 50:12, 50:15, 50:18, 53:16, 54:16, 56:20, 81:15, 82:19, 83:16, 90:20, 91:1, 92:1, 96:3, 113:1, 120:16, 122:5 surface 35:18, 37:14, 42:7, 91:14, 92:10 surgeries 29:11 surgery 28:20
--	---	--	--

surgical 29:5, 29:8, 84:1 sworn 7:21, 8:3, 9:14, 124:23, 125:6 synonymous 20:14 systemic 55:1 T take 10:10, 19:6, 20:20, 26:21, 31:14, 44:18, 45:21, 46:1, 66:18, 66:19, 83:5, 89:18, 95:13, 95:17, 96:1, 107:11, 121:20 taken 2:5, 12:14, 12:17, 46:15, 96:16, 118:4, 125:8 taking 9:19, 10:5 talk 6:6, 9:20, 20:8, 32:10, 39:14 target 41:5, 42:17, 42:19, 57:2 targeting 41:20 tattoo 29:16 taught 29:21 teaching 29:6, 29:11, 55:11, 55:16, 55:22, 56:1 tech 18:19	technical-related 6:19 technically 38:16 technician 3:37, 6:2, 18:15, 18:22, 22:3, 27:1, 27:16, 31:5, 31:22, 65:4, 65:6, 66:16, 89:4, 89:11, 89:16, 89:21, 97:8, 102:1, 102:7, 102:12, 102:17, 102:20, 103:2, 103:15, 112:17, 113:17, 113:21, 114:3, 122:9, 122:14, 122:21 technologies 44:17, 45:2, 45:16, 45:18, 56:17 technology 15:2, 15:5, 29:9, 44:18, 115:22 teenagers 60:17, 60:21 tell 9:15, 36:20, 40:1, 49:2, 63:4, 63:14, 106:16 telling 80:7 tells 94:22 telltale 32:6 ten 61:8 term 38:1, 38:2, 57:7, 111:9 terminology 78:6	terrycloth 91:21, 91:22 testified 8:5, 14:2, 63:6, 105:19, 106:1, 118:22 testify 8:4 testifying 9:16, 68:6 testimony 33:12, 96:22, 120:2, 125:9 texas 2:9, 7:16, 7:18, 125:2 text 73:16, 87:1, 87:4, 87:10 texture 35:18 th 2:7, 3:30, 43:3, 125:16, 126:5 thank 6:2, 6:19, 7:22, 17:13, 22:5, 28:8, 32:2, 56:10, 67:21, 82:5, 87:8, 96:6, 103:17, 113:5, 114:15, 118:8, 122:5, 122:17 thanks 102:22 therapeutic 15:20 therapies 94:18 therapy 5:17, 15:21, 31:13, 33:10, 36:15, 51:8, 51:11, 51:16, 52:21, 56:17, 56:19, 56:20,	57:9, 60:8, 61:4, 61:9, 62:3, 63:17, 73:18, 91:7, 95:2, 106:20, 107:17, 108:3, 110:16, 114:21, 115:14 thermal 38:9 they'd 92:5 thick 91:20, 91:22 thing 21:16, 27:20, 35:12, 49:3, 58:22, 94:7 things 33:8, 33:15 think 29:20, 40:4, 50:7, 53:20, 60:2, 67:13, 68:17, 94:13, 94:14, 95:15, 95:18, 102:8, 107:16, 117:1, 122:1 third 120:6 thousands 44:7, 44:8 three 38:7, 60:1, 60:21, 60:22, 71:3, 71:13, 73:16, 84:18, 111:3 through 11:14, 18:21, 19:2, 19:7, 103:8 throughout 10:6 tight 110:4 time 6:15, 6:21,
---	--	--	--

6:22, 12:16, 20:20, 39:2, 45:20, 53:15, 55:6, 55:22, 56:3, 80:17, 86:20, 87:19, 88:1, 88:7, 88:10, 88:13, 95:12, 95:16, 96:8, 101:9, 106:4, 106:21, 109:18, 119:17, 120:3, 120:11, 120:19, 121:1, 121:4, 121:21, 122:11, 122:19 times 34:6, 60:13, 60:22, 62:19, 87:13 titled 15:20 to--hour 87:18, 87:22, 88:11, 88:13 today 8:12, 8:20, 9:5, 9:20, 10:14, 12:11, 20:1, 69:18, 96:22, 111:16 today's 14:4 together 56:8, 71:17 tongue-in-cheek 49:2 took 70:17 top 36:1, 71:15, 76:5, 77:13, 79:10, 79:19, 85:21, 99:6, 113:15 top-down 70:6 topical 36:16, 36:19,	51:6, 52:6, 52:7, 52:11, 52:15, 53:19, 54:19 total 17:9, 23:18 touching 82:22, 91:4 touchup 47:15, 47:19, 48:1, 48:4, 48:6, 48:7, 48:13, 48:18 towel 91:21, 92:1 trademark 1:1, 9:2 trained 44:22, 88:15, 88:16, 88:18, 90:17, 90:19, 90:20, 92:20 training 45:6, 54:13, 54:17, 55:3, 56:8, 83:6, 119:16 trainings 118:15, 118:20, 119:4, 119:12, 120:3, 120:5, 120:10, 120:18 transcript 6:18, 11:1, 11:4, 121:19 transplantation 29:15 tray 84:2 treat 35:14, 42:20, 43:6, 44:1, 44:13, 52:2, 53:19, 60:4, 60:15, 62:3, 80:22, 81:6, 82:12, 91:11, 91:21, 92:7,	93:12, 93:21, 94:11, 94:12, 101:3 treated 40:6, 53:17, 91:5, 106:4 treating 20:8, 35:6, 50:3, 51:1, 51:4, 51:10, 51:20, 52:10, 53:5, 53:12, 58:11, 81:15, 90:21, 101:8 treatment 35:13, 35:20, 36:2, 36:16, 37:3, 37:21, 38:4, 41:14, 47:16, 47:20, 48:8, 50:2, 50:7, 50:22, 51:3, 53:8, 53:10, 53:14, 59:15, 59:19, 60:2, 60:3, 60:12, 72:15, 72:18, 73:19, 82:4, 82:7, 83:10, 84:16, 85:7, 87:21, 88:4, 90:11, 91:6, 93:4, 93:22, 94:15, 94:21, 98:1, 98:4, 100:5, 105:20, 105:21, 107:11, 109:22, 110:15, 111:2, 112:2, 112:3 treatments 15:22, 29:17, 29:18, 35:21, 36:10, 43:20, 49:6, 49:9, 49:14, 49:22, 50:4, 51:17, 52:6, 56:2,	58:3, 58:6, 58:9, 60:1, 60:12, 62:20, 63:2, 63:5, 81:14, 94:17, 95:9 tremendously 106:15 trial 1:4 tried 88:6 tropical 52:7 true 19:18, 38:17, 41:16, 83:12, 119:6, 119:7, 124:15, 125:8 truth 8:4, 8:5, 9:15 truthfully 12:11 try 9:6, 100:12 trying 41:5, 44:13, 44:18, 53:18, 57:2, 72:8 tubes 71:4, 71:13, 71:15, 71:21, 84:19 tucked 92:2 turn 71:19, 72:7, 89:14, 93:6, 93:13, 94:1 turned 95:2 twenty 107:20 twice 60:18 two 15:21, 27:9, 45:8, 52:5,
---	---	--	--

54:21, 55:21, 58:12, 60:7, 60:22, 61:8, 71:15, 74:17, 75:21, 77:1, 77:2, 77:4, 77:5, 77:7, 80:3, 91:12, 92:8, 104:4 two-thirds 47:8 tx 3:14 type 36:18, 48:15 types 13:16, 29:10, 52:5, 55:6, 108:14 typical 48:6 typically 56:22, 60:17, 84:4, 91:9, 91:12, 92:5, 115:21	undergraduate 54:16 underneath 70:15, 73:16, 87:4 understand 8:20, 9:11, 9:12, 9:13, 10:3, 10:4, 10:11, 10:12, 11:5, 11:8, 45:1, 68:5, 68:22, 69:12, 96:10, 104:15, 105:3, 111:18 understanding 68:9, 68:12, 68:14, 69:19 understood 20:15, 21:8, 21:22, 77:5 unedited 6:17 uniformly 70:21 unique 55:1, 55:8 unit 92:4 united 1:1, 5:4, 9:2 unless 10:17, 108:9 unquote 100:22 until 9:21, 10:1, 17:8, 17:11, 57:7, 61:2, 61:7 unusual 12:8 update 20:7 updated 27:8 uploaded 102:9 url 99:6	usage 114:17, 115:10 usc 29:3, 30:4, 55:5, 55:12, 88:6 use 5:15, 19:2, 39:18, 41:7, 48:21, 50:2, 50:22, 51:3, 51:10, 51:19, 52:14, 56:22, 60:14, 70:18, 70:20, 77:6, 83:22, 84:15, 85:18, 88:12, 91:12, 91:17, 92:8, 106:10, 111:19, 114:20, 119:2 uses 15:20, 88:11 using 15:9, 21:2, 36:16, 37:22, 42:6, 52:2, 52:17, 56:21, 57:21, 63:7, 71:18, 88:7, 91:7, 92:16, 94:10, 97:13, 106:1, 106:8, 107:5, 108:4 usually 94:2	41:15, 41:22, 42:20, 45:8, 48:8 veins 29:16 versus 53:17, 94:4, 106:17, 107:20 vessel 48:10, 48:13 vessels 48:9 via 6:14 video 6:11, 6:13, 81:18, 90:9 videoconference 14:19 videoconferenced 1:20, 2:3 videos 90:6 view 69:1, 70:6, 76:20 viewable 89:13 visible 41:19 visual 95:1 vitae 5:12, 27:7 voluntary 29:5 volunteer 55:16 vulgaris 16:1
U		V	W
u-device 93:14 u-shaped 74:15, 78:12, 79:11, 79:21, 98:10 ucla 55:18 uh-huh 20:22, 23:3, 39:22, 81:9, 115:12 unable 6:13 unclear 39:10 under 9:10, 12:9, 30:3, 38:5, 115:10		vague 75:11, 79:14, 106:12 varies 60:16, 61:10 variety 33:8, 53:13, 55:5, 55:15 vbeam 36:9, 41:13,	wait 9:21, 10:1, 37:19, 107:20 waiver 69:6 walk 36:20

wall 84:5 walls 58:21 want 22:7, 31:18, 35:22, 37:2, 37:6, 37:9, 41:4, 42:16, 46:7, 50:12, 53:7, 53:17, 54:6, 60:2, 72:16, 81:14, 85:20, 85:22, 87:1, 89:13, 90:3, 94:5, 100:10, 110:1, 121:18, 122:3, 122:10, 122:15, 122:19 wanted 48:12, 94:12, 122:10 warning 101:8 water 38:10 wavelength 38:19, 40:19, 40:20, 40:21, 41:2, 41:7, 41:16, 41:17 wavelengths 41:14 way 23:20, 35:3, 37:11, 38:21, 45:1, 47:8, 48:20, 68:19, 72:13, 72:22, 86:14, 90:17, 116:18, 120:4, 125:22 ways 50:18 we'll 10:5, 11:8, 39:14, 52:14,	96:5, 96:13, 121:22 we're 37:22, 49:3, 50:19, 57:2, 60:2, 60:8, 60:9, 67:12, 75:21, 76:3, 77:1, 77:2, 77:7, 77:21, 78:3, 78:19, 83:3, 83:14, 84:10, 84:20, 94:16, 94:20, 96:8, 96:11, 96:12, 102:15 we've 45:19, 60:21, 83:6, 83:8, 83:16, 95:13 web 5:17, 99:7 website 31:13, 62:1, 62:17, 63:4, 86:12, 86:15, 87:3, 90:8, 99:13, 99:15 week 53:15, 60:18, 60:22 weekly 29:6 weighting 33:8, 33:11 whatever 111:15, 121:22 wheel 84:2, 93:17 whenever 23:9 whereof 126:4 whether 13:2, 42:6, 63:9, 72:13, 73:1, 86:14, 86:15, 99:21,	117:9, 120:5, 120:10, 120:18, 121:14 white 88:8 whole 8:4, 83:18 wide 43:10, 43:12, 43:14, 55:15 willing 52:14, 52:20 wisdom 32:5 within 27:9, 70:7, 81:16, 82:20, 83:4, 83:15, 83:17, 83:21, 84:14, 95:6, 116:22, 125:2 witness 2:5, 7:17, 7:21, 12:21, 13:11, 13:13, 13:17, 13:20, 14:7, 15:15, 16:22, 17:22, 18:14, 19:11, 23:3, 23:7, 24:1, 24:6, 27:15, 27:18, 28:5, 28:8, 28:12, 42:11, 46:6, 46:9, 65:8, 68:12, 96:3, 114:1, 115:2, 115:4, 115:7, 117:21, 118:9, 119:9, 119:20, 120:8, 120:14, 120:22, 124:24, 125:5, 125:9, 126:4 wonderful 28:14 word 19:7	words 109:1 work 17:5, 17:7, 22:19, 22:22, 23:19, 27:13, 30:4, 30:5, 45:2, 55:21, 89:7 works 56:19, 57:4 worries 123:1 wrap 93:17 wraps 93:14 wrinkle 49:8 wrinkles 32:11, 33:18, 34:3, 35:16, 49:17 wrinkling 49:18 write 21:9 writing 101:19 wrong 67:17 www 99:7 X xl 25:13, 103:21, 104:16, 104:22, 110:13 Y yeah 45:15, 56:7, 66:9, 66:11, 67:22, 68:16, 69:8, 70:12, 71:12, 89:15, 95:15, 96:10,
--	---	--	---

Transcript of Heather J. Roberts, M.D., FAAD
Conducted on July 25, 2025

157

101:18, 102:10, 112:8, 117:18, 121:20, 122:18 year 25:2, 55:21 years 13:3, 27:9, 30:14, 32:6, 35:1, 53:3, 55:9, 56:8, 56:16, 57:22, 58:2, 58:14, 59:3, 71:19, 88:5, 90:17, 106:13, 106:18, 107:10, 118:20 yep 27:1 yes-or-no 68:21, 69:16, 107:16 york 3:31 yourself 6:14, 21:9, 36:4, 54:9, 57:10 Z zap 48:12 zero 40:3 zoom 17:2, 88:20, 89:3, 89:5, 89:10, 100:11 zoomed 89:3 \$ \$50 60:12 \$800 105:21 \$900 22:10 0 01312 1:13	02110 3:6 028 16:5, 24:2, 24:11, 69:1, 69:15 0335 3:7 04 96:17, 96:19 05 46:14, 46:15 07 2:7, 6:22, 125:16 071 66:11, 67:12 1 1,100 38:22 10 43:3, 43:10, 46:4, 46:8, 46:14, 46:15, 46:16, 46:18, 67:13, 95:17, 96:2, 126:13 100 43:14 1000 3:12 101 3:21 1014 5:4, 65:3, 65:5, 65:11, 67:14, 67:15, 67:17, 67:22, 70:1 1015 67:12 10169 3:31 1022 5:7, 112:14, 112:18, 113:3, 113:4, 113:9	103 5:21 11 4:3, 96:15, 96:16 11,697,028 1:14, 9:1 112 5:7 118 4:6 12 2:8, 53:3, 79:13, 79:22, 96:13, 96:17, 96:19, 118:3, 118:4, 118:5, 118:7, 123:3, 123:4, 125:17 121 4:7 124 4:8 125 4:9 13 20:21, 40:7, 56:12, 56:15, 97:10 14 62:19, 87:15, 87:18, 87:22, 88:11, 88:13 15 14:13, 16:12, 17:4, 17:10, 17:12, 21:17, 46:16, 46:18, 95:17 16 91:18 1600 3:15 18 5:9, 87:15, 87:18, 87:22, 88:11, 88:13 18,500 104:16, 105:4	1902 3:24 1999 12:18 2 2,400 58:3, 58:6, 95:8, 106:4 20 1:22, 2:7, 40:5, 43:12, 55:9, 56:16, 57:22, 58:2, 59:3, 62:7, 62:10, 71:19, 88:5, 106:13, 106:18, 107:10, 118:20, 125:16 2001 30:16, 30:19 2004 57:19, 58:7, 63:8, 63:11, 106:2, 107:21, 108:5 2015 5:9, 18:14, 18:17, 18:19, 19:5, 19:12, 19:18, 39:2, 54:4, 97:6 2016 5:12, 26:22, 27:3, 27:5, 28:4 2018 5:15, 73:14, 81:19, 85:1, 85:12, 85:13, 85:15, 90:4 2022 113:3 2023 5:17, 31:4, 31:6, 31:8, 31:9, 47:5 2024 1:13, 5:18,
---	---	--	--

Transcript of Heather J. Roberts, M.D., FAAD
Conducted on July 25, 2025

158

18:2, 18:4, 18:7, 86:3, 86:16, 98:14, 98:15, 98:17, 99:3, 99:18, 105:9, 105:12, 107:19 202401312 8:22 2025 1:22, 2:7, 25:1, 107:18, 107:20, 108:4, 124:25, 125:16, 126:5 2049 5:21, 101:22, 102:3, 103:6, 117:1 20850 126:18 21 58:14 212 3:32 214 62:18 230 3:29 24 30:14 25 1:22, 2:7, 86:2, 125:16 26 3:30, 126:13 27 5:12, 126:5 28 57:12 3 30 35:1 3000 3:22 31 5:17, 61:17,	61:19, 126:13 32 62:16 33 57:17, 70:15 34 97:10, 99:4 3400 3:32 35 73:7, 73:9, 73:13 351 3:32 36 93:6, 96:15, 96:16 37 20:21 374 3:15 3767 126:19 3900 3:5 3d 70:17 4 40 52:14, 91:18, 118:3, 118:4 400 126:17 406 3:7 415 3:24 4170 57:14 43 21:18, 80:20 433 126:19 45 96:4, 96:13, 117:22 451 126:16	480 38:20 5 50 52:14, 118:5, 118:7 500 60:3 55 2:8, 123:3, 123:4, 125:17 5729 7:18, 126:12 573 3:24 595 41:16, 41:18 6 6,223,071 5:5, 65:12 600 60:3 617 3:7 6400 3:13 65 5:4 686 126:15 7 70 52:4 713 3:15 77002 3:14 8 8,000 59:9 80 52:4 800 38:22, 59:15,	105:22 85 5:15 888 126:19 9 9 2:7, 6:22, 96:4, 125:16 90 37:19, 37:20, 48:9, 76:19, 80:4, 88:16 94111 3:23 98 5:18
--	--	---	---